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BRCA1 germline mutations are associated with significantly increased lifetime risk of 
developing breast and ovarian cancers. However, taking into account considerable differences 
in disease manifestation among mutation carriers, it is probable that various BRCA1 mutations 
lead to formation of distinct phenotypes and haploinsufficiency effects and that both type and 
location of the mutation could play an important role in cancer initiation. PARP inhibitors are 
currently one of the most promising agents for treatment of tumors deficient in BRCA1 or 
BRCA2. However, cancer patients carrying germline mutation in BRCA1/2 genes show a big 
variability in the responses to PARP inhibitors in clinical trials. Thus, we were interested in 
investigating whether and how BRCA1 mutation type influences the response of cells to PARP 
inhibitors. 
We used a panel of lymphoblastoid cell lines (LCLs) derived either from heterozygous 
BRCA1 mutation carriers or non-carriers in order to study haploinsufficiency effects of various 
mutation types (truncating vs missense). LCLs carrying truncating mutations showed 
significantly lower BRCA1 mRNA and protein levels and higher levels of gamma-H2AX than 
control cells or LCLs harboring missense mutation, indicating increased spontaneous DNA 
damage in these cells. However, cells carrying either of the BRCA1 mutation type showed 
impaired RAD51 foci formation, suggesting defective repair in mutated cells and a possible 
mechanism of increased susceptibility of mutation carriers to cancer. 
Moreover, gene expression analysis revealed that LCLs carrying missense mutations 
showed more distinct expression profile than cells with truncating mutations when compared 
to controls, suggesting that different mutations may lead to distinct phenotypes and 
haploinsufficiency effects. Importantly, decreased expression of immune response-related 
genes in cells harboring missense mutation indicates possible mechanisms of breast cancer 
initiation in carriers of these particular BRCA1 mutations. 
At the present study, we are describing for the first time that cells derived from carries of 
missense mutations in the BRCA1 BRCT domain show higher sensitivity to PARP inhibitor 
olaparib than cells with truncating mutations or WTs. These results indicate that carriers of 
different mutation types could benefit from the treatment in a distinct way and that they 
could display different toxicity to the agent. Taking into account the presence of non-degraded 
mutated protein in cells carrying missense mutation there is a possibility that the missense 
mutants act in a dominant negative manner on the WT protein function. Thus, we hypothesize 
that there is a competition between mutated and WT BRCA1 protein in the recruitment to 
DNA damage sites, which could lead to an alteration the DNA repair process and decreased 
viability of cells carrying BRCA1 missense mutation. The mechanism of increased sensitivity of 
cells carrying missense mutation to olaparib could be, at least partially, also related to possible 
changes in olaparib-specific BRCA1 protein interactors in mutated cells. In addition, regulation 
of miR-222-3p and its target FOS by olaparib treatment in cells carrying missense mutation 
suggest a possible use of these molecules as markers of sensitivity to the treatment. 
In summary, our results bring new insights on how various heterozygous mutations in 
BRCA1 could lead to impairment of BRCA1 function and show a strong evidence about 
haploinsufficiency in BRCA1 mutation carriers. Moreover, our results indicate that carriers of 
different types of BRCA1 mutations could benefit from the treatment in a distinct way and that 
could show different toxicity to the PARP inhibitor olaparib.  
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Mutaciones germinales en BRCA1 están asociadas con un incremento significativo en el 
riesgo a desarrollar cáncer de mama y ovario. Sin embargo, teniendo en cuenta las 
considerables diferencias en la manifestación de la enfermedad en portadoras de mutación, es 
probable que distintas mutaciones en BRCA1 den lugar a distintos fenotipos y efectos de 
haploinsuficiencia, y que tanto el tipo de mutación como su localización puedan jugar un papel 
importante en la iniciación del cáncer. Los inhibidores de PARP son actualmente uno de los 
agentes más prometedores para el tratamiento de tumores deficientes en BRCA1 o BRCA2. No 
obstante, enfermas de cáncer portadoras de una mutación germinal en los genes BRCA1/2 
muestran una gran variabilidad en la respuesta a inhibidores de PARP en ensayos clínicos. Por 
estos motivos, nuestro interés ha radicado en investigar si el tipo de mutación en BRCA1 
influye en la respuesta de las células a inhibidores de PARP y en caso afirmativo, averiguar cuál 
es el mecanismo responsable. 
Utilizamos un panel de células linfoblastoides (LCLs) derivadas bien de portadoras 
heterocigotas de mutación en BRCA1 o bien de no portadoras de mutación con el objetivo de 
estudiar los efectos de haploinsuficiencia que tienen distintos tipos de mutaciones (de 
proteína truncada vs de cambio de aminoácido). Las LCLs portadoras de mutaciones de 
proteína truncada mostraron niveles significativamente menores de ARNm y proteína BRCA1 y 
niveles superiores de gamma-H2AX que las células control o que las LCLs portadoras de 
mutación de cambio de aminoácido, lo que indica un incremento espontáneo en el daño del 
ADN en estas células. Sin embargo, las células portadoras tanto de un tipo como de otro de 
mutación, mostraron una disminución en la formación de focos de RAD51, lo que sugiere una 
reparación defectuosa en las células mutadas y un posible mecanismo de aumento de 
susceptibilidad al cáncer en portadoras de mutación. 
Además, los análisis de expresión génica revelaron que las LCLs portadoras de mutaciones 
de cambio de aminoácido mostraban perfiles de expresión más diferentes que las células con 
mutaciones de proteína truncada al compararlas con los controles, lo que sugiere que 
mutaciones diferentes podrían dar lugar a distintos fenotipos y efectos de haploinsuficiencia. 
De manera importante, la disminución en la expresión de genes asociados a la respuesta 
inmune observada en las células portadoras de mutaciones de cambio de aminoácido, indica 
un posible mecanismo de iniciación del cáncer de mama en portadoras de estas mutaciones 
concretas en BRCA1. 
En el presente estudio, describimos por primera vez que las células derivadas de 
portadoras de mutaciones de cambio de aminoácido en el dominio BRCT de BRCA1 muestran 
mayor sensibilidad al inhibidor de PARP olaparib que las células con mutaciones de proteína 
truncada o WT. Estos resultados indican que portadoras de distintos tipos de mutación podrían 
beneficiarse del tratamiento de distinta manera y que podrían mostrar diferente toxicidad al 
agente. Teniendo en cuenta la presencia de proteína mutada no degradada en las células 
portadoras de mutación de cambio de aminoácido, cabría la posibilidad de que los mutantes 
de cambio de aminoácido tengan un efecto dominante-negativo sobre la función de la 
proteína WT. De esta manera, planteamos la hipótesis de que existe una competición entre la 
proteína mutada y la WT en el reclutamiento a los sitios de daño en el ADN, lo que podría dar 
lugar a una alteración en el proceso de reparación del ADN y una disminución en la viabilidad 
de las células portadoras de mutaciones de cambio de aminoácido en BRCA1. El mecanismo de 
incremento en la sensibilidad a olaparib de las células portadoras de mutaciones de cambio de 
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aminoácido podría estar asociado, al menos en parte, a posibles cambios en las proteínas 
específicas para olaparib que interaccionan con BRCA1 en las células mutadas. Además, la 
regulación del miR-222-3p y su diana FOS por el tratamiento de olaparib en células portadoras 
de mutaciones de cambio de aminoácido sugiere un posible uso de estas moléculas como 
marcadores de sensibilidad al tratamiento. 
En resumen, nuestros resultados aportan nuevos conocimientos sobre cómo distintas 
mutaciones heterocigotas en BRCA1 podrían dar lugar a defectos en la función de BRCA1 y 
muestran gran evidencia de haploinsuficiencia en portadoras de mutaciones en BRCA1.  
Además, nuestros resultados indican que portadoras de distintos tipos de mutaciones en 
BRCA1 podrían beneficiarse del tratamiento de distinta forma y podrían mostrar toxicidades 
diferentes al inhibidor de PARP olaparib. 
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1. Breast anatomy 
Human breast is a bilateral organ which has a pivotal function in synthesis, secretion, and 
delivery of breast milk to an infant (Hassiotou and Geddes 2013). The anatomy of the female 
mammary gland changes dramatically throughout the woman´s life, depending on the 
physiological stage of breast development. A post-pubertal mammary gland consists of 
glandular (secretory) and adipose (fatty) tissue which is supported by fibrous connections 
called suspensory (Cooper´s) ligaments (Ali and Coombes 2002) (Figure 1A). The secretory 
tissue is organized into 15–20 lobes, connected with the nipple by a series of branched ducts 
which store and transport secreted milk during lactation. 
There are two major types of epithelium in the ductal network: the secretory luminal 
epithelium, which form the inner single layer-part of the duct, and the basal component, which 
is represented by the contractile myoepithelial cells at the outer layer of a duct and is in a 
direct contact with the adjacent fibroblast stroma (Sternlicht 2006; LaMarca and Rosen 2008) 
(Figure 1B). All types of epithelial cells in the mammary gland originate from multipotent 
mammary stem cells and are maintained due to their proliferation (LaMarca and Rosen 2008). 
 
 
Figure 1. A) Anatomy of the human mammary gland (adapted from Ali and Coombes, 2002). B) 
Schematic view of the morphology of a developing mammary duct (adapted from Sternlicht, 2006). 
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2. Breast cancer 
2.1. Epidemiology 
Breast cancer is a complex, heterogeneous disease which is both the most frequent and 
the most deadly cancer in women worldwide (Ferlay and Soerjomataram, 2013). There were 
about 1.67 million new breast cancer cases diagnosed in 2012 worldwide, which accounts for 
roughly one fourth of all cancers. 
 
Figure 2. A) Estimated age-standardized breast cancer incidence worldwide per 100,000 in 2012 (Ferlay 
and Soerjomataram, 2013). B) Global age-standardized rate of breast cancer mortality per 100,000 
population in 2012 (Ferlay and Soerjomataram, 2013). 
39 
 
There is a clear variability in the breast cancer incidence (Figure 2A) and mortality 
(Figure 2B) rates between less and more developed regions (Ferlay and Soerjomataram, 2013). 
The incidence rates differ almost 4-fold depending on the world region, ranging from 27 per 
100,000 in Middle Africa and Eastern Asia to 96 per 100,000 in Western Europe. The rates of 
breast cancer mortality were significantly reduced over the last decade, mainly due to better 
availability and use of medical practices such as screening programs, availability and quality of 
treatment. Despite this substantial progress in more developed regions, poor countries have 
not followed the mortality decline. Because of the more favorable survival of breast cancer in 
developed (high incidence) countries the mortality rates are in general smaller across the 
world than those for incidence. In less developed countries, breast cancer is the most common 
cause of cancer death. On the other hand, most female cancer patients living in the more 
developed regions die from lung cancer, and breast cancer is considered as a second cause of 
cancer death in these countries. 
 
2.2 Risk factors 
Due to its increasing incidence, there has been an enormous effort to identify factors 
which can modulate the chance of breast cancer development throughout the women´s 
lifetime. One of the highest risk factor (after a gender, i.e. being a woman) for breast cancer is 
age, with the highest incidence rate found among older women (Cancer Research UK, 2014). 
Between years 2009 and 2011, 80% of all breast cancer cases in the UK were diagnosed in 
women older than 50 years old, and 24% of new breast cancer patients were 75 years old or 
older. 
Having a personal history or a close relative affected with breast cancer also considerably 
increase the risk of being diagnosed with the same disease (Curtis et al., 2006; Cancer 
Research UK, 2014). Women (and men) with a first-degree relative (mother, sister, daughter, 
father, or brother) previously affected with breast cancer are at increased risk of developing 
breast cancer as well, and the risk is further elevated if more than one first-degree relative 
developed breast cancer (Collaborative_Group_on_Hormonal_Factors_in_Breast_Cancer 
2001). When compared to women with no family history, the risk of breast cancer is 1.8 times 
higher for women with 1 first-degree female relative diagnosed with this disease, almost 3 
times higher if the woman has 2 affected relatives, and nearly 4 times higher for women with 3 
or more affected relatives. 
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Table 1. Risk factors for breast cancer in women. Relative risk is a comparison of the absolute risk of 
disease among people with a particular risk factor to the risk among people without that risk factor. The 
relative risk which is higher than 1.0 means that the risk is higher among people with the particular risk 
factor than among people without the factor. (Breast Cancer Fact & Figures 2013–2014) 
 
 
 
The observed difference in incidence rates worldwide is believed to be at least partially 
caused by the variability in reproductive patterns and other hormonal factors (Cancer 
Research UK, 2014). The breast cancer risk has been reported to be elevated by younger age at 
menarche (the first menstrual period), late menopause, lower parity (having no or fewer 
children), and older age at first giving birth, which are factors related to exposure to sex 
hormones. On the other hand, higher parity and breastfeeding at least for 6 months are 
associated with reduced risk of breast cancer development. In addition, current or recent use 
of combined oestrogen-progestogen oral contraceptives, or using combined hormonal therapy 
for menopausal symptoms is also classified as a breast cancer risk factor. Furthermore, recent 
Relative risk  Factor
> 4.0 Age (65+ vs. <65 years, although risk increases across all  ages until  age 80)
Biopsy-confirmed atypical hyperplasia
Certain inherited genetic mutations for breast cancer (BRCA1 and/or BRCA2)
Lobular carcinoma in situ
Mammographically dense breasts
Personal history of early onset (<40 years) breast cancer
Two or more first-degree relatives with breast cancer diagnosed at an early age
2.1‒4.0 Personal history of breast cancer (40+ years)
High endogenous estrogen or testosterone levels (postmenopausal)
High-dose radiation to chest
One first-degree relative with breast cancer
1.1‒2.0 Alcohol consumption
Ashkenazi (Eastern European) Jewish heritage
Diethylstilbestrol (DES) exposure
Early menarche (<12 years)
Height (tall)
High socioeconomic status
Late age at first full-term pregnancy (>30 years)
Late menopause (>55 years)
Never breastfed a child
No full-term pregnancies
Obesity (postmenopausal)/adult weight gain
Personal history of endometrium, ovary, or colon cancer
Recent and long-term use of menopausal hormone therapy containing estrogen and progestin
Recent oral contraceptive use
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studies suggested that there is a correlation between certain reproductive risk factors and 
development of particular breast cancer subtypes (Anderson, Schwab et al. 2014). 
The fact that women who migrate from low to high risk countries show an increased 
incidence of breast cancer suggests the existence of other, non-reproduction-related, risk 
factors (Ziegler, Hoover et al. 1993). Higher breast density (higher percentage of non-fat tissue) 
was found to be independent on sex hormones and increases risk of breast cancer up to 5 
times. Other lifestyle and environmental factors which are associated with increased risk of 
breast cancer development are exposure to ionizing radiation, high-fat diet, increased alcohol 
consumption, smoking, night-shifts etc. The summary of known risk factors for breast cancer 
with the values of relative risk when compared to general population is presented in Table 1 
(Breast Cancer Fact & Figures 2013–2014). 
 
2.3 Breast cancer classification 
Breast cancer can be divided into ductal and lobular carcinoma which is either located 
in situ or spreads into an adjacent tissue and gives rise to an invasive disease (Vuong, Simpson 
et al. 2014). Such histological classification of breast cancer was established because it has 
been thought for a long time that distinct histological types originate from distinct 
microanatomical structures of normal mammary gland (ducts versus lobes). However, Wellings 
and colleagues demonstrated long time ago that most of the in situ and invasive breast cancers 
actually arise from the terminal duct/lobular unit, independently on the histological type 
(Wellings and Jensen 1973; Wellings, Jensen et al. 1975). Therefore, the current division into 
ductal or lobular carcinoma rather describes the cytological features and 
immunohistochemical profiles, than the site of origin of the breast tumor (Weigelt and Reis-
Filho 2009). 
The traditional classification of invasive breast cancers, which helps to guide the breast 
cancer patient management, is performed based on the histological type and grade, the 
presence of lymphovascular invasion and lymph-node metastasis, and the expression of 
certain predictive biomarkers (Correa Geyer and Reis-Filho 2009). 
 
 
 
42 
 
2.3.1 Histological types, grade and stage 
According to the newest edition of the WHO Classification of Tumours of the Breast there 
are more than 21 subtypes of invasive breast carcinoma (Lakhani and Ellis, 2012), the “invasive 
ductal carcinoma of no special type” representing the majority of breast cancer cases (40–
75%). The other subtypes are classified as morphologically distinct “special” types of breast 
cancer. 
Histological grading is a powerful prognostic factor which evaluates the proportion of 
tubule formation, degree of nuclear pleomorphism, and the mitotic index. The combination of 
such features gives rise to grades 1–3: grade 1 being the most differentiated and having a very 
good clinical outcome, grade 3 representing the least differentiated tumors which tend to 
recur and metastasize early (Elston and Ellis 1991; Rakha, Reis-Filho et al. 2010a). 
In addition to tumor grading, breast cancer is also staged by the conventional TNM system 
which uses both clinical and pathology information, including the primary tumor size (T), the 
status of regional lymph nodes (N), and spread to distant metastatic sites (M) (Edge and 
Compton 2010). 
 
2.3.2 Traditional predictive biomarkers and current therapeutic strategies 
The expression of hormone receptors, including oestrogen (ER) and progesterone (PR) 
receptors, and human epidermal growth factor receptor 2 (HER2) are currently routinely used 
in clinical practice worldwide (Vuong, Simpson et al. 2014). 
The majority of breast cancers, up to 75% of all cases, are ER-positive (ER+), and these 
tumors are usually well differentiated and associated with better clinical outcome (Anderson, 
Chatterjee et al. 2002). PR-positive (PR+) tumors account for about 60% of breast cancer. The 
progesterone receptor gene is known to be regulated by oestrogen and its expression is 
therefore considered as an indicator of an intact ER pathway (Lanari, Lamb et al. 2009). The 
determination of the ER/PR status has the main clinical value particularly when estimating the 
likelihood of the response of patient to a traditional endocrine therapy (Rakha, Reis-Filho et al. 
2010a). There are several strategies how to block the oestrogen action by the pharmacologic 
endocrine therapy, including direct inhibition of the receptor by selective ER modulators (e.g. 
tamoxifen), by using selective ER down-regulators (e.g. fulvestrant), or inhibition of oestrogen 
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production by treatment with aromatase inhibitor antagonists (Smith and Dowsett 2003; 
EBCTCG 2005). 
Another commonly used indicator of poor prognosis is HER2, which is overexpressed in up 
to 20% of invasive breast cancers, and more than half of these tumors are hormone receptor 
negative (ER- and PR-) (Slamon, Clark et al. 1987; Dandachi, Dietze et al. 2002). ERBB2 gene 
(encoding the HER2 protein) amplification or HER2 protein overexpression is used in the clinics 
as a predictor of response to the humanized anti-HER2-specific monoclonal antibody, also 
known as trastuzumab or Herceptin (Vuong, Simpson et al. 2014). This treatment is used both 
in patients with HER2+ advanced disease and in the adjuvant setting for HER2+ early breast 
cancer. In addition, small-molecule drugs targeting the internal tyrosine kinase domain of 
HER2 (e.g. lapatinib) or vaccines are being developed as a new cancer therapies (Rakha, Reis-
Filho et al. 2010b, 2010). 
There is a distinct group of aggressive tumors representing the triple-negative breast 
cancer (TNBC), which displays characteristic morphology, presentation, behavior and outcome. 
These tumors account for about 15% of breast cancer cases and are characterized by the 
absence of expression of ER and PR and the lack of HER2 overexpression (Oakman, Viale et al. 
2010). From the clinical point of view, this group of tumors is associated with poor prognosis 
and high risk of distant recurrence, and there is currently no available targeted therapy 
because, unlike the ER+/PR+/HER2+ tumors, these tumors do not respond to hormonal or 
HER2-targeted therapy (Dent, Trudeau et al. 2007; Brunello, Borgato et al. 2013). The current 
standard treatment option for patients with early-stage TNBC is a combination of 
anthracycline- and taxane-based chemotherapy regimen (Curigliano and Goldhirsch 2011). 
 
2.3.3 Molecular subtypes 
There has been an enormous effort in the past decade to unravel the molecular 
characteristics of breast cancer by applying various microarray-based high-throughput 
technologies in order to identify new prognostic and predictive subgroups and to individualize 
the therapy (van 't Veer, Dai et al. 2002; Potti, Dressman et al. 2006; Sotiriou, Wirapati et al. 
2006). 
The first important finding, while analyzing the diversity of primary invasive breast cancers, 
described by Perou et al. already in 2000, led to the development of a molecular classification 
of breast tumors into four distinct molecular subtypes (basal-like, ERBB2-overexpressing, 
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normal breast-like, and luminal) and suggested that these subtypes might need to be treated 
as distinct diseases in the future (Perou, Sorlie et al. 2000). More detailed investigation by 
Sorlie and colleagues resulted in a further stratification of the luminal subtype into at least two 
separate groups, “luminal A” and “luminal B”, with distinct expression profiles and clinical 
outcomes for patients (Sorlie, Perou et al. 2001; Sorlie, Tibshirani et al. 2003). 
The basal-like subtype is characterized by high expression of CK5 and CK17 (cytokeratine 5, 
cytokeratine 17), and other genes which are typical for basal/myoepithelial cells, including 
LAMC1 (laminin γ1), ANXA8 (annexin A8) and CDH3 (cadherin 3, type 1). In addition, basal-like 
tumors also often overexpress EGFR (epidermal growth factor receptor). Tumors of the ERBB2-
overexpressing subtype often overexpress genes from the same chromosome region as ERBB2 
(e.g. GRB7, MED24 and MED1) and show high expression of genes related to cell cycle 
progression. The Luminal A tumors are characterized by expression of luminal CK8 amd CK18 
(cytokeratine 8, cytokeratine 18), they typically highly express transcription factors GATA3, 
FOXA1 and XBP1, and overexpress Cyclin D1. On the other hand, the Luminal B subtype is 
typical for tumors which are more proliferative and show different pattern of mutations (e.g. 
in TP53 and PIK3CA genes) than Luminal A tumors (Perou, Sorlie et al. 2000; Norum, Andersen 
et al. 2014). 
Further characterization of the molecular subtypes revealed that they also display a 
characteristic pattern of ER, PR and HER2 expression. As shown in Table 2, the majority of 
luminal tumors show ER+ status, and the basal-like molecular subtype is, on the contrary, 
frequently associated with ER-, PR- and no overexpression of HER2 (TNBC phenotype) (Weigelt 
and Reis-Filho 2009). However, taking into account that only 77% of basal-like breast cancers 
are triple-negative and, vice versa, 71–91% of TNBC are of the basal-like phenotype, it is clear 
that TNBC and basal-like breast cancers overlap but they represent distinct subtypes (Oakman, 
Viale et al. 2010). 
Both the triple-negative and basal-like breast cancer subtypes have been found to be 
frequently linked to the hereditary form of breast cancer caused by a germline mutation in the 
high-penetrance breast cancer susceptibility gene BRCA1, (Sorlie, Tibshirani et al. 2003; 
Penault-Llorca and Viale 2012). Interestingly, this gene has been found to be mutated also in 
some sporadic triple-negative breast tumors, which showed similar clinical outcomes and 
histological characteristics as tumors found in BRCA1 mutation carriers (Burgess and Puhalla 
2014). Such shared phenotypes between sporadic and hereditary BRCA1-mutated tumors have 
led to a formation of a special term, “BRCAness”, which groups together sporadic cancers with 
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BRCA-like functional abnormalities, and which could help to identify tumors sensitive to 
treatments designed for familiar-BRCA tumors (Turner, Tutt et al. 2004). 
 
 
Table 2. ER and HER2 status in molecular subtypes of breast cancer (Weigelt and Reis-Filho, 2009). 
 
#
ER expression evaluated by immunohistochemistry or enzyme immunoassay. 
‡
Only 3+ immunohistochemical expression or amplification as defined by chromogenic or fluorescence in situ 
hybridization was considered positive. 
§
Only studies where data on ER were defined by immunohistochemistry or enzyme immunoassay and HER2 by 
immunohistochemistry and/or in situ hybridization were included. 
 
 
2.4 Hereditary breast cancer 
The majority of breast cancer cases are considered as sporadic, they are characterized by a 
later age of onset and by lacking a particular pattern of inheritance. However, there is a 
substantial percentage (up to 15%) of new breast cancer patients that report a positive family 
history of breast cancer and are thus considered as having a “familial breast cancer”  
(Collaborative_Group_on_Hormonal_Factors_in_Breast_Cancer 2001). Familial cancer is 
characterized by a higher number of cancer cases within a family than statistically expected, 
unknown inheritance model, and variable age of onset (Berliner and Fay 2007). But these 
features do not reliably identify women carrying a germline alteration responsible for the 
initiation of breast cancer since the familial clustering of breast cancer can be a consequence 
of several non-genetic factors: random clustering of sporadic cases in large families with many 
older women, similar environmental and/or lifestyle factors. In contrast to the familial breast 
cancer, hereditary breast cancer represents 5–10% of breast cancer cases, has a more clear 
pattern of inheritance, earlier age of onset (<50 years of age), and multiple primary and/or 
bilateral cancers. 
Breast cancer            
molecular subtypes§
ER-positive           
median % (range)#
HER2-positive         
median % (range)‡
Basal-like 16.6 (4.5–45.8) 13.6 (8.2–50)
HER2 55.7 (16.7–67.4) 72.7 (45.9–80)
Normal breast-like 83 (42.9–92.3) 10 (4.5–28.6)
Luminal 97.2 (85.4–100) 3.3 (1.5–27.3)
Luminal A 96.3 (81.8–98.8) 1.2 (1.2–1.2)
Luminal B 96.7 (87–100) 1.8 (1.8–1.8)
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2.4.1 Breast cancer susceptibility genes 
Up to date several high-, moderate- and low-susceptibility genes, which significantly 
increase the risk of breast and ovarian cancer in the mutation carriers, have been identified 
(Figures 3A, 3B) (Foulkes 2008; Couch, Nathanson et al. 2014). As shown in the Figure 3A, 
mutations in the high-susceptibility genes (such as BRCA1 and BRCA2) are associated with high 
relative risk of breast and ovarian cancer but are very rare in population. On the contrary, low-
penetrance alleles (such as variants identified in Genome Wide Association Studies (GWAS) are 
frequent in a population but they confer a low relative risk. 
 
 
Figure 3. A) Graph of the relationship between relative risk and minor allele frequency of high-, 
moderate- and low-susceptibility alleles for breast cancer (adapted from Foulkes, 2008). B) High-, 
moderate- and low-penetrance genes  predisposing mutation carriers to breast cancer (adapted from 
Couch et al., 2014). 
 
 
2.4.1.1 High-penetrance breast cancer genes 
The positional cloning experiments from early 1990s resulted in the identification of two 
highly penetrant breast and ovarian cancer susceptibility genes: BRCA1, located on 
chromosome 17, and BRCA2 on chromosome 13 (Miki, Swensen et al. 1994; Wooster, 
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Neuhausen et al. 1994). The estimated average cumulative risk of developing breast cancer by 
the age of 70 is in the range of 52–65% in BRCA1 mutation carriers and 45–49% in BRCA2 
mutation carriers. Similarly, the corresponding estimates for ovarian cancer are 22–40% and 
11–18%, for BRCA1 and BRCA2 mutation carriers respectively (Antoniou, Pharoah et al. 2003; 
Chen, Iversen et al. 2006; Chen and Parmigiani 2007; Milne, Osorio et al. 2008). However, it is 
important to note that the estimates of the average cumulative cancer risk in BRCA1/2-
mutation carriers vary widely, depending on the target population and design of the study. 
Although germline mutations in BRCA genes increase woman´s lifetime risk of developing 
breast and ovarian cancers, these mutations represent only about 15% of breast cancers with a 
hereditary component (Figure 3B) (Couch, Nathanson et al. 2014). Additional high-penetrance 
genes (TP53, PTEN, LKB1/STK11 and CDH1) have been described to be connected to various 
familial syndromes-associated increased incidence of breast cancer and are estimated to 
account for approximately 3% of hereditary breast cancers (Seal, Thompson et al. 2006; 
Rahman, Seal et al. 2007; Meindl, Hellebrand et al. 2010; Shamseldin, Elfaki et al. 2012). 
 
2.4.1.2 Moderate- and low-susceptibility breast cancer genes 
About 4% of patients with a strong family history of breast cancer could be explained by 
mutations in moderate-susceptibility genes (Figure 3B), which show odds ratio around 2-4 and 
incomplete segregation. A considerable proportion of these genes are members of the Fanconi 
anemia pathway (PALB2, BRIP1, RAD51C), or other DNA repair pathways (CHEK2, ATM, 
RAD51D, and BARD1) (Couch, Nathanson et al. 2014). 
Furthermore, numerous common low-susceptibility genetic variants have been liked to 
breast cancer through genome-wide association (GWAS) studies (Michailidou, Hall et al. 2013). 
The odds ratios of these SNPs (single nucleotide polymorphisms) refer to a slight increase or 
reduction in risk and explain about 14% of hereditary breast cancer cases (Couch, Nathanson 
et al. 2014). In addition to the known variants, further 14% of SNPs, which have not been 
discovered yet, are predicted to contribute to hereditary breast cancer. Taking into account 
the small effect of these variants, the clinical utility of a single variant is limited, however, 
combined effects of particular variants could be useful for prevention, prediction of the cancer 
risk and response to treatment. 
Despite the intensive efforts for identification other breast cancer susceptibility genes, our 
current knowledge about genes involved in predisposition of mutation carriers to breast 
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cancer explains only half of the cases. There are still about 50% of familial breast cancer 
patients which are negative for mutation in any of the previously mentioned genes. These 
cases are commonly called as BRCAX (or non-BRCA1/2), and their familial inheritance can be 
explained either by an unknown mutation in yet not discovered moderate-penetrance breast 
cancer gene, or by a polygenic inheritance model of several low-penetrance loci (Melchor and 
Benitez 2013; Couch, Nathanson et al. 2014). However, the current standard of testing for 
mutations in the high-susceptibility genes, in particular BRCA1 and BRCA2, is still the most 
powerful predictor of the likelihood of developing hereditary breast and ovarian cancers. 
 
2.4.2 BRCA1 gene 
BRCA1 gene was mapped to the human chromosome 17q21 in early 1990s based on its 
linkage to breast and/or ovarian cancer families (Miki, Swensen et al. 1994). The gene consists 
of 24 exons, covers about 110 kb of DNA and encodes for a large (1863 amino acid long) 
predominantly nuclear protein with a molecular mass of 220 kDa. 
 
2.4.2.1 BRCA1 functions 
There are several function-specific domains in BRCA1 protein (Figure 4A) (Roy, Chun et al. 
2011). The N-terminus contains a RING domain, through which BRCA1 associates with BRCA1-
associated RING domain protein 1 (BARD1). There are also two nuclear localization signal (NLS) 
sequences, from which only the first one is required for the transport of BRCA1 protein from 
cytosol into nucleus (Caestecker and Van de Walle 2013). The central region of BRCA1 is 
phosphorylated by CHK2 kinase at serine residue in position 988. In the C-terminus of BRCA1, 
there are a coiled-coil domain that binds to partner and localizer of BRCA2 (PALB2), a SQ/TQ 
cluster domain (SCD) with approximately 10 potential ataxia-telangiectasia mutated (ATM) 
prosphorylation sites, and two tandem BRCA1-C-terminal (BRCT) domains through which 
BRCA1 binds to ATM-phosphorylated Abraxas, CtBP-interacting protein (CtIP) and BRCA1-
interacting protein C-terminal helicase 1 (BRIP1) (Roy, Chun et al. 2011). 
As clear from the Figures 4A and 4B, numerous protein complexes interact with BRCA1, 
allowing the complexity of functions that BRCA1 is able to perform in cells. During the past two 
decades, BRCA1 has been found to play a critical role in various cellular processes, including 
DNA repair by distinct pathways, cell cycle checkpoints control, centrosome amplification, 
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transcriptional activation of target genes, and ubiquitin ligation (Narod and Foulkes 2004; 
Drost and Jonkers 2014). 
 
 
Figure 4. A) BRCA1 protein domains and phosphorylation sites (based on Roy et al., 2012).  B) BRCA1 
functions and protein interactors (adapted from Narod and Foulkes, 2004). 
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2.4.2.2 BRCA1 mutations  
According to The Breast Cancer Information Core (BIC), there are more than 1800 unique 
sequence variants in BRCA1, including intronic changes, missense mutations, and small in-
frame deletions and insertions (Couch, Nathanson et al. 2014); The Breast Cancer Information 
Core – BIC at http://research.nhgri.nih.gov/bic/). 
The majority of BRCA1 mutations are deletions, duplications, splice site, nonsense and 
frameshift mutations, and more than 80% of them lead to the occurrence of a premature 
termination codon (PTC) and truncation of the BRCA1 coding sequence (The Breast Cancer 
Information Core – BIC). Most of these truncated transcripts are then subjected to degradation 
by a cellular surveillance mechanism called nonsense-mediated mRNA decay (NMD) pathway 
(Perrin-Vidoz, Sinilnikova et al. 2002). 
On the other hand, missense mutations in BRCA1 are in general much less common than 
other types of mutations. Pathogenic and highly penetrant missense mutations are mainly 
situated in the RING and BRCT domains, which play a critical role in the DNA repair activity of 
BRCA1 (Roy, Chun et al. 2011); The Breast Cancer Information Core – BIC). However, there are 
lots of BRCA1 variants which are spread along the coding sequence and are of unknown clinical 
significance (VUS). In the past years, there has been an appreciable effort of the ENIGMA 
consortia (Evidence-based Network for the Interpretation of Germline Mutant Alleles) to 
develop quantitative risk prediction methods which would help to decide whether a particular 
variant is pathogenic or of neutral/low effect. 
Some BRCA1 mutations are population-specific, and these founder mutations usually arise 
in small geographically or culturally isolated ethnic groups. The best example is a population of 
Ashkenazi Jewish, in which approximately 1.2% of individuals carry one of the two BRCA1 
founder mutations: c.68_69delAG (traditionally known as 185delAG), c.5266dupC (also known 
as 5382insC) (Roa, Boyd et al. 1996). Focusing on the Spanish population, the most common 
mutation is also 185delAG, and two of the three most recurrent BRCA1 mutations are 
missense mutations (R71G, A1708E), which are rather rare in other populations (Milne, Osorio 
et al. 2008). 
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2.4.2.3 Heterogeneity among BRCA1-mutation carriers 
BRCA1 is considered as a typical tumor suppressor gene due to its role in DNA repair and 
genomic maintenance and its inactivation therefore leads to an accumulation of genetic 
defects and increase of genomic instability. Even though carrying an inherited mutation in 
BRCA1 gene predisposes carriers to breast, ovarian and other cancers, there are considerable 
differences in the disease manifestation between mutation carriers. 
Such interindividual variability could be explained by distinct environmental and genetic 
effects, as well as location and type of mutations in BRCA1 gene (Couch, Nathanson et al. 
2014). The efforts of a Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) have led 
to a discovery of numerous common genetic modifiers of breast cancer risk identified by 
GWAS studies. Since its establishment in 2006 and with samples from more than 40,000 
BRCA1/2 mutation carriers, CIMBA provides an outstanding sample size for reliable evaluation 
of associations between single-nucleotide polymorphisms (SNPs) and cancer risk (Chenevix-
Trench, Milne et al. 2007). Taking into account the identified modifiers of the risk, the 
estimated cumulative risk of developing breast cancer by the age of 80 is in the range of 81–
100% (Couch, Wang et al. 2013). 
Furthermore, early studies by Gayther and colleagues showed a significant correlation 
between the location of BRCA1 mutation and the ratio of breast/ovarian cancer incidence 
(Gayther, Warren et al. 1995). Nonsense and frameshift BRCA1 mutations which are located in 
the ovarian cancer cluster region (OCCR) were found to be significantly associated with 
increased risk of ovarian risk than mutations in other regions of BRCA1. In addition to the 
location of the BRCA1 mutation, the type of mutation seems to also play a relevant role in the 
biology of breast cancer. Waddell et al. have demonstrated that expression profiles of 
lymphoblastoid cell lines (LCLs) depend on the BRCA1 mutation type (Waddell, Ten Haaf et al. 
2008). They observed differences in response to stress when comparing cells harboring 
missense and truncating mutations and WT controls, suggesting that the remaining WT alelle 
in cells carrying heterozygous BRCA1 mutation might not be sufficient for normal cell function 
and that such haploinsufficiency thus results in an abnormal phenotype. 
 
2.4.2.4 BRCA1 haploinsufficiency 
BRCA1 behaves as a tumor suppressor, following the Knudson’s “two-hit” hypothesis, 
based on which, mutation in one allele of the gene is not sufficient to enable cancer 
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development and a second “hit” is necessary in order to impair its function (Knudson 1971). 
However, several studies indicate that mutation in one allele could already affect some of 
BRCA1 functions and that such haploinsufficiency might accelerate the loss of the second allele 
and lead to carcinogenesis. 
Several gene expression studies published in last years support the idea about BRCA1 
haploinsufficiency in mutation carriers. Comparison of BRCA1-mutation carriers-derived cells 
(LCLs, fibroblasts, primary breast and ovarian epithelial cells) with WT cells showed clear 
differences in their expression profiles when exposed to ionizing irradiation (IR) or other 
treatments (Kote-Jarai, Matthews et al. 2006; Bellacosa, Godwin et al. 2010; Walker, 
Thompson et al. 2010; Salmon, Salmon-Divon et al. 2013). Recently, using a big panel of un-
treated LCLs, Feilotter and colleagues for the first time distinguished BRCA1 mutation carriers 
from WT controls according to the gene expression patterns under basal conditions (Feilotter, 
Michel et al. 2014). 
Importantly, BRCA1 seems not to be the only DNA repair gene showing signs of 
haploinsufficiency. Recent studies with lymphoblastoid cells lines (LCLs) showed that 
monoallelic mutations in PALB2 or MUTYH can lead to genomic instability and DNA damage 
response defects (Nikkila, Parplys et al. 2013; Grasso, Giacomini et al. 2014). These findings 
indicate the role of DNA-repair-gene haploinsufficiency in genomic instability and 
carcinogenesis, however, more studies will be necessary in order to fully understand the 
variability between mutation carriers and the initial steps of breast carcinogenesis. 
 
3. PARP inhibitors 
Poly (ADP-ribose) polymerases (PARPs) belong to a family of enzymes which catalyze a 
post-translational modification (poly ADP-ribosylation) of target proteins by the transfer of 
ADP-ribose (Ame, Spenlehauer et al. 2004). The family consists of at least 18 members which 
contain a conserved catalytic domain and are encoded by distinct genes. PARP enzymes have 
been found to play an important role in nucleic acid metabolism, modulation of chromatin 
structure, DNA synthesis, and DNA repair (Morales, Li et al. 2014). The first and most 
characterized member of the PARP family is PARP1, sharing a high similarity in its catalytic 
domain with PARP2. Within the past decade, inhibition of these enzymes became a hot topic 
when investigating new targeted therapies for hereditary breast and ovarian cancers and other 
malignancies. 
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3. 1 Synthetic lethality and other models of action of PARP inhibitors 
Synthetic lethality is a concept when a combination of mutations in two genes results in 
cell death, but there is no negative effect on cells when only one of these two genes is 
compromised (Kaelin 2005). The occurrence of a synthetic lethal interaction between a tumor 
suppressor gene and other gene, e.g. PARP1, makes this other gene a potential therapeutic 
target (Figure 5). 
As BRCA1 is an important player in the repair of DNA damage, BRCA1-deficient cells need 
to rely on other members of the DNA repair machinery. This fact makes them sensitive to the 
drugs which target those repair pathways, such as PARP inhibitors. PARP enzymes are involved 
in a DNA single-strand break (SSB) repair pathway (Helleday 2011). If inhibited, naturally 
occurring SSBs cannot be repaired, leading to a formation of double-strand breaks (DSBs) and 
replication fork collapse. Unrepaired DSBs in BRCA-deficient cells then result in cell death 
(Drost and Jonkers 2014). This is the basis of a synthetic lethal interaction between BRCA1/2 
and PARP1 which was described for the first time by Farmer et al. and which has become a 
promising therapeutic strategy for breast, ovarian and other cancers (Bryant, Schultz et al. 
2005; Farmer, McCabe et al. 2005). 
 
 
 
 
 
 
 
 
 
Figure 5. Mechanism of synthetic lethality between BRCA deficiency and PARP inhibition (adapted from 
Banerjee et al., 2010). 
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Since 2005, modifications of the initial synthetic lethal principle as well as new 
mechanisms for the increased sensitivity of BRCA1/2-deficient cells to PARP inhibitors have 
been proposed. One of the alternative mechanisms is PARP trapping (Strom, Johansson et al. 
2011; Murai, Huang et al. 2012). Ström and colleagues showed that treatment with PARP 
inhibitor traps its principal target PARP1 on the SSB, leading to a creation of PARP-SSB 
intermediate complex which could be more toxic than unrepaired SSB (Strom, Johansson et al. 
2011). Another mechanism proposes that PARP inhibition could upregulate the error-prone 
NHEJ (non-homologous end joining) DNA repair pathway, which would cause genomic 
instability and potential lethality (Patel, Sarkaria et al. 2011). In addition, it has also been 
suggested that the role of PARP1 in reactivating DNA replication forks could be altered by 
PARP inhibitors and could lead to increased sensitivity in BRCA-mutation carriers (Helleday 
2011). It is possible that a combination of previously mentioned mechanisms takes part in 
killing cancer cells in carriers of BRCA1/2 mutations and understanding of all consequences of 
PARP inhibition still remains an open question for the future. 
 
3.2 PARP inhibitor trials in BRCA1/2-mutated breast cancers 
Numerous PARP inhibitors are currently being tested in preclinical or clinical trials in 
patients with sporadic/hereditary breast, ovarian and other cancers. There are currently 4 
distinct PARP inhibitors (including olaparib, veliparib, rucaparib and BMN 673) involved in 
numerous clinical trials in BRCA-associated breast cancer patients (Table 3) (Drost and Jonkers 
2014). These PARP inhibitors are administered either as a monotherapy or in combination with 
chemotherapy, depending on a study design. 
The encouraging results from phase II studies have allowed to proceed with more 
advanced, phase III, trials using either of the four PARP inhibitors in BRCA1/2-mutated breast 
and ovarian cancers (Burgess and Puhalla 2014; Liu, Konstantinopoulos et al. 2014). There are 
currently 7 phase III clinical trials (ClinicalTrials.gov identifiers: NCT01945775, NCT02163694, 
NCT01905592, NCT01847274, NCT01844986, NCT01874353, NCT01968213) recruiting carriers 
of BRCA mutation suffering from breast or ovarian cancer (www.ClinicalTrials.gov). 
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Table 3. Current clinical trials involving PARP inhibitors in BRCA-associated breast cancer (based on 
Drost and Jonkers, 2014). Search criteria in ClinicalTrials.gov: PARP inhibitors, breast cancer, BRCA. 
 
 
 
3.3 Sensitivity and resistance to PARP inhibitors 
Although more than 60% of the patients with germline mutation in BRCA1 and BRCA2 
genes showed clinical benefit after treatment with PARP inhibitor olaparib, a substantial 
fraction of patients was resistant to the agent (Fong, Boss et al. 2009). 
Several mechanisms of acquired resistance to PARP inhibitors have been hypothesized and 
are expected to be multifactorial in etiology. One of the expected cause of resistence to PARP 
inhibition is the occurence of secondary reversion mutations in BRCA1/2 genes (Barber, 
Sandhu et al. 2013). Another way of loosing sensitivity to the treatment with PARP inhibitors is 
by maintaining a certain basal activity of mutated BRCA1. Drost et al. showed that C61G 
mutation in RING domain does not disrupt all the BRCA1 functions and that this basal activity is 
sufficient to reduce sensitivity to PARP inhibitors (Drost, Bouwman et al. 2011). There are also 
BRCA-independent mechanisms of acquired resistance to PARP inhibitors. For example, 
resistance of a mouse model for BRCA1-associated breast cancer to olaparib has been 
described to be driven by upregulation of P-glycoprotein efflux pumps (Rottenberg, Jaspers et 
al. 2008). In addition, a loss of 53BP1 has been found to partially restore the homologous 
recombination (HR) pathway in BRCA1-deficient cells (Jaspers, Kersbergen et al. 2013). It has 
also been recently proposed that overexpression of PARP1 could be responsible for a fraction 
of PARP inhibitor-resistant cases (Gilabert, Launay et al. 2014). 
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Taking into consideration the phenotypic variability between BRCA1 mutation carriers and 
the described changes in response to PARP inhibitors in carriers of various BRCA1 mutations 
(as illustrated in Figure 6), it would be interesting to investigate the differences in therapy 
response among carriers of various BRCA1 founder mutations. Clearly, further investigation is 
necessary for the best utilization of these potent compounds in the clinics. 
 
 
 
 
 
 
 
 
 
Figure 6. Effect of BRCA1 mutation status on the response to PARP inhibiting therapy (adapted from 
Caestecker et al., 2013). DSB HR = double strand break homologous recombination; PARPi = poly (ADP-
ribose) polymerase inhibiting therapy. 
OBJECTIVES
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Considering the variability in disease manifestation among BRCA1 mutation carriers, we 
hypothesized that different types of mutations may give rise to various phenotypes. Therefore, 
the primary objective of this work was to investigate whether different germline BRCA1 
mutations (missense versus truncating) lead to distinct haploinsufficiency effects. 
Moreover, cancer patients carrying germline mutation in BRCA1 gene show a wide range 
of responses to PARP inhibitors. Thus, we were interested in investigating whether and how 
BRCA1 mutation type influences the response of cells to PARP inhibitors. 
 
Taking into account the general objectives, the specific goals of this thesis were: 
 
1. Investigate BRCA1 haploinsufficiency in carriers of missense or truncating mutations in 
BRCA1 gene by checking DNA repair capacity, gene and miRNA expression profiles. 
 
2. Check the response of cells harboring missense or truncating BRCA1 mutations to 
various PARP inhibitors and investigate the factors which could potentially influence 
the response of cells to PARP inhibitors. 
 
3. Using funtional studies and gene and miRNA expression profiling, explore the 
mechanism of variability in response to PARP inhibitor olaparib depending on BRCA1 
mutation status. 
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1 Cell lines and cell culture 
 
1.1 Patient-derived cell lines 
Lymphoblastoid cell lines (LCLs) were established by EBV-transformation of peripheral 
blood mononuclear cells (PBMC). Briefly, the PBMC were isolated from blood samples with 
Ficol (Sigma; #F2637), washed 1x with 1xPBS (Lonza; #BE17-516F), resuspended in freezing 
media (complete growth medium with 10% DMSO; see detailed information about growth 
conditions in the “Cell culture and treatments” section) and shipped frozen to our 
collaborators from the Cancer Epigenetics and Biology Program at the Bellvitge Biomedical 
Research Institute (IDIBELL) in Barcelona, where the cell immortalization was carried out. 5 
million PBMCs were incubated (3 hours, 37ºC) with 1ml of supernatant of 0.45 μm filtered 
culture of the B95.8 strain EBV producer cell line. 3ml of a complete growth medium was 
added and cells were treated with Phytohemaglutinin-L (final concentration 10 μg/ml). Cells 
were checked daily and media was changed when necessary during the next 2–3 months, until 
the immortalization was achieved. 
Blood samples from 15 women carrying heterozygous mutations in BRCA1 (BRCA1+/-) and 
6 non-carrier relatives (BRCA1+/+) were collected to establish the final panel of LCLs. Mutational 
analysis had been previously performed by Sanger sequencing (primers available upon 
request). None of the individuals included in the study had personal antecedents of cancer. 
Detailed information about the individuals included in the study is shown in Table 4. 
 
1.2 Other cell lines 
Breast cancer cell line MDA-MB-231, derived from a sporadic breast cancer tumor, was 
obtained from the Cancer Epigenetics Group at the Bellvitge Institute for Biomedical Research 
(Barcelona, Spain). MDA-MB-231 was transduced by BRCA1-specific short-hairpin RNAs 
(shRNAs) or control shRNA (shScramble) and these newly generated cell lines were then used 
to confirm a synthetic lethal interaction between BRCA1 and PARP1. 
HEK293FT cells were provided by the lab of Dr. Alvaro Monteiro during my 4-month short 
stay at the Moffitt Cancer Center (USA, FL, Tampa). 
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Table 4. List of lymphoblastoid cell lines (LCLs) 
LCL ID
1
 BRCA1 mutation
2
 Mutation type Exon NMD
3,4 
Age
5 
06S179-L WT WT - - 31 
09S797-L
a
 WT WT - - 27 
10S889-Lb WT WT - - 20 
11S66-Lc WT WT - - 30 
11S534-Ld WT WT - - 50 
11S954-L WT WT - - 35 
06S1159-L c.5123C>A; p.Ala1708Glu missense 18 - 37 
10S890-Lb c.5123C>A; p.Ala1708Glu missense 18 - 25 
10S1202-L c.5123C>A; p.Ala1708Glu missense 18 - 53 
11S65-L
e 
c.5117G>A; p.Gly1706Glu missense 18 - 31 
11S67-Le c.5117G>A; p.Gly1706Glu missense 18 - 34 
07S1291-L c.3239T>A; p.Leu1080X nonsense 11 + 34 
06S1167-L c.3331_3334delCAAG; p.Gln1111fs frameshift 11 + 33 
09S491-L c.815_824dup10; p.Thr276fs frameshift 11 + 24 
09S546-L c.212+1G>A; p.? splice 5 Unknown 42 
09S798-La c.2410C>T; p.Gln804X nonsense 11 + 24 
10S44-L c.4309delT; p.Ser1437fs frameshift 13 + 22 
10S1177-Lc c.68_69delAG; p.Glu23fs frameshift 2 re-initiation* 27 
11S376-Lf c.212+1G>A; p.? splice 5 unknown 39 
11S384-Lf c.212+1G>A; p.? splice 5 unknown 75 
11S1004-L
d 
c.981_982delAT; p.Cys328X frameshift 11 + 25 
1a-f indicate which LCLs were established from relatives (sisters or mother/daughter) 
2Mutation nomenclature listed uses GenBank reference sequences NM_007294.3 with numbering 
starting at the A of the first ATG, following the journal guidelines (www.hgvs.org/mutnomen); p.?, 
unknown protein nomenclature (variant causing skipping of exon 5 of BRCA1) 
3
NMD not activated by the variant (-), degradation of mutated transcript by NMD (+), not known 
functional interpretation (unknown), variant leading to translation re-initiation (re-initiation) 
4
NMD status determined by prediction according to the BIC database (BRCA1 master list from 19 July 
2013) or experimentally investigated (Buisson, Anczukow et al. 2006) (*) 
5
Age of women at the time of blood extraction to establish LCL 
 
 
1.3 Lentiviral constructs 
BRCA1 gene down-regulation was performed in MDA-MB-231 cell line using shRNAmir 
target gene set obtained from Open Biosystems (13 human GIPZ lentiviral shRNAmir individual 
clones; #RHS4531). The design of shRNAmir is based on the primary microRNA-30 transcript 
and allows processing via the endogenous RNAi pathway resulting in more specific and 
guaranteed gene silencing. 
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Six different shRNA constructs were transduced (details in Supplementary Table S1), and 
two of them, which provided the best knockdown efficiency, were selected to silence BRCA1 in 
the breast cancer cell line. A non-targeting shRNA vector (pGIPZ-shRNAmir-Scramble) was used 
as a negative control. 
 
1.4 Generation of stable cell lines 
Schematic overview of the generation of stable cell line is shown in Figure 7. Each human 
GIPZ lentiviral shRNAmir vector was co-transfected with lentiviral packaging plasmids (helper 
plasmids VSVG and psPAX2; kindly provided by Dr. F. Real from CNIO) into 293FT cells 
(Invitrogen) using transfection reagent Fugene 6 (Promega; #E2691) following the 
manufacturer’s instructions. The virus-containing supernatants were collected 36 hours post-
transfection and ﬁltered. MDA-MB-231 cells were then infected with lentiviral supernatant 
supplemented with 1ug/ml polybrene (Santa Cruz; #sc-134220). The stably-transduced cells 
were selected by adding medium containing 1 mg/ml puromycin (Sigma; #P9620). 
Downregulation of BRCA1 expression was conﬁrmed by Western blotting and quantitative RT-
PCR. 
 
 
Figure 7. Schematic overview of shRNA-mediated BRCA1 knockdown in MDA-MB-231 breast cancer 
cell line. 
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1.5 Cell culture and treatments 
LCLs were cultured in RPMI-1640 media (Sigma-Aldrich; #R8758) supplemented with non-
heat inactivated 20% fetal bovine serum (Sigma-Aldrich; #F7524), 1% penicillin-streptomycin 
(Gibco; #15070-063) and 0.5% Fungizone (Gibco; #15290-018). Cell culture was carried out in 
25 cm2 flasks (Corning; #3056) and LCLs were maintained in exponential growth by daily 
dilution to 1 x 106 cells per ml of full media. Early passages (passage 1–10) of LCLs were used 
for all experiments. MDA-MB-231 and HEK293FT cells were grown in RPMI-1640 or DMEM 
media, respectively, and both media were complemented with 10% fetal bovine serum, 1% 
penicillin-streptomycin, and 0.5% Fungizone. All cells were maintained in an atmosphere of 5% 
CO2 at 37°C. 
Where noted, DNA damage was induced by exposure to 10 Gy ionizing radiation (MDS 
Nordion Gammacell 1000). Following treatment, cells were allowed to recover for 4 hours 
under normal growth conditions prior to fixation for immunofluorescence experiments. In 
experiments with PARP inhibitors, LCLs were incubated with either olaparib = OLP (Axon 
Medchem; #1464) or veliparib = VLP (Axon Medchem; #1593) for indicated period of time at 
37°C in 5% CO2 atmosphere and treatment with DMSO (Sigma; #D8418) dissolvent was used as 
a control. 
 
2 RNA expression analysis 
 
2.1 RNA extraction and quantification  
RNA from an early passage of LCLs or MDA-MB-231 cell line (parental cell line or stably 
expressing shRNA) was extracted using TRIzol Reagent (Invitrogen; #15596-026) according to 
the manufacturer´s instructions. In the case of LCLs, ten million cells from each cell line, either 
non-treated or treated with DMSO or olaparib, were used for RNA isolation. The equal amount 
of cells utilized for RNA extraction was used in order to prevent a selective loss of certain 
miRNAs from total RNA (Kim, Yeo et al. 2012). RNA quality and quantity was determined using 
LabChip technology on an Agilent 2100 BioAnalyser (Agilent Technologies). All samples had the 
value of RNA integrity number (RIN) in the range 7.5 to 10.0. 
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2.2  Real-time PCR analysis 
For detection of BRCA1 gene expression levels, 500 ng of total RNA was reverse-
transcribed by High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems; #4368814) 
according to the manufacturer´s instructions. Using labeled probes (Roche Universal 
ProbeLibrary; #04683633001) and TaqMan Universal PCR Mix (Applied Biosystems; #4304437) 
the cDNAs were analyzed by quantitative RT-PCR assay in an ABI Prism Sequence Detection 
System 7900HT (Applied Biosystems). Following oligonucleotides were used in the quantitative 
RT-PCR: F-primer 5´-TTAAAGAAAGAAAAATGCTGA-3’ and R-primer 5´-
GGTGGTTTCTTCCATTGACC-3’ for detection of BRCA1 expression; F-primer 5´-
CTGGAGGACGACAAGGAAAA -3’ and R-primer 5´-TGTTGCTACCGATCACCGTA-3’ to detect 
PARP1 gene expression. Expression levels of HPRT1 and MRLP19 were used as internal controls 
and enabled normalization of samples. Three independent experiments were performed and 
the relative expression was calculated using a comparative Ct method. 
 
3 Protein-based assays 
 
3.1 Protein extract preparation 
In order to detect levels of certain proteins in cells by Western blotting, whole cell lysates 
or proteins from a nuclear fraction were prepared. Exponentially growing cells were harvested 
by centrifugation and washed 2x with ice-cold PBS (Lonza; #BE17-516F). 
For detection of BRCA1, a protein subcellular fractionation was performed. Briefly, washed 
cellular pellet was resuspended in RSB buffer (Tris 10 mM pH 7.5, NaCl 10 mM, MgCl2 3 mM, 
protease inhibitor) and incubated 20 min on ice. Nuclei were sedimented by centrifugation and 
the supernatant (cytoplasmic fraction) was transferred into a new tube and stored at -20°C. In 
order to remove any contaminating cytoplasm the pellet (nuclei) was washed 1x with full RSB 
buffer and 2x with RSB buffer which did not contain protease inhibitors. Nuclear pellet was 
then resuspended in NB buffer (Tris 10 mM pH 7.5, NaCl 0.4 mM, EDTA 1 mM, protease 
inhibitor) by pipetting several times and incubated 15 min at 4°C while shaking. Samples were 
centrifuged and the concentration of the nuclear fraction of proteins (supernatant) was 
determined using DC Protein Assay Kit II (Bio-Rad; #500-0112) with BSA as a standard. 
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For PARP1 and PAR detection, whole cell lysates were prepared. Shortly, cellular pellets 
were washed twice with ice cold PBS and lysed in RIPA buffer (Sigma-Aldrich; #R0278) 
containing protease inhibitor (Roche; #11697498001) for 1 hour on ice. Lysates were 
centrifuged at 16,000 g for 20 min at 4°C and supernatants (containing proteins from whole 
cell lysate) were transferred into new tubes for further quantification of proteins with Bio-Rad 
protein assay kit as in the case of nuclear proteins. 
 
3.2 SDS-PAGE and Western blotting 
For the detection of BRCA1 protein, 75 or 100 ug of nuclear proteins from LCLs or MDA-
MB-231 cells, respectively, was loaded per well of NuPAGE 3–8% Tris-Acetate gel (Invitrogen). 
To detect other proteins, 75 ug of whole cell lysate per well was loaded into NuPAGE 4–12% 
Bis-Tris gel (Invitrogen). Separated proteins were transferred to a nitrocellulose membrane 
(Whatman) using the NuPage transfer system (Invitrogen) and the membrane was then 
blocked in Tris buffered saline containing 0.05% Tween-20 (TBS-T) and 5% milk. Blots were 
probed with following primary antibodies: mouse anti-BRCA1 (Calbiochem; #OP92), rabbit 
anti-PARP1 (Cell Signaling; #9542), rabbit anti-PAR (Calbiochem; #528815), rabbit anti-RAD51 
(Santa Cruz; #sc-8349), rabbit anti-GAL4-DBD (Santa Cruz; #sc-577). Mouse anti-β-actin (Sigma; 
#A5441) was used as a loading control for whole cell lysates, and mouse anti-HSC70/HSP70 
antibody (Enzo; #ADI-SPA-820-D) or rabbit anti-nucleolin (Abcam; #ab22758) served as loading 
controls for nuclear proteins. The secondary antibodies were HRP-conjugated (Dako) and the 
immunoblots were developed using the ECL system (GE Healthcare). Western blot X-ray films 
(Kodak) were scanned and analyzed using ImageJ software. 
 
3.3 Mass spectrometry (performed during my short stay at the MOFFITT Cancer 
Center) 
DMSO- or OLP (16μM)-treated HEK293FT cells overexpressing pNTAP-BRCA1-BRCT 
construct (previously described by Woods, Mesquita et al. 2012) were collected, lysed and 
proteins were extracted. A previously described protocol was used (Woods, Mesquita et al. 
2012) to perform the mass spectrometry experiment. Briefly, protein fractions created by SDS-
PAGE were excised, destained, reduced, alkylated and digested with trypsin (Promega). 
Peptides were eluted from the gel and concentrated using vacuum centrifugation. A nanoflow 
liquid chromatograph (U3000, Dionex, Sunnyvale, CA) coupled to an electrospray ion trap mass 
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spectrometer (LTQ or LTQ-Orbitrap, Thermo, San Jose, CA) was used for tandem mass 
spectrometry peptide sequencing. Raw files were searched against SwissProt human database 
(release year 2014) using a search engine Mascot (Matrix Science) (Perkins, Pappin et al. 1999). 
Assignments were manually verified by inspection of the tandem mass spectra and coalesced 
into Scaffold reports (v.2.0, available at www.proteomesoftware.com) for statistical analysis 
and data presentation. The Scaffold software was used to validate MS-MS based peptide and 
protein identifications. After applying the SAINT (Significance Analysis of INTeractome) 
algorithm and setting a probability threshold of 0.8−1, a final list of 121 protein interactors was 
selected. 
 
4 Functional and cell-based assays 
 
4.1 DNA repair evaluation by confocal microscopy 
Where noted, DNA damage was induced by exposure to ionizing radiation (MDS Nordion 
Gammacell 1000). Control and 10-Gy irradiated LCLs were cultured 4 hours before fixation 
with 4% paraformaldehyde (Aname; #15710). Two hours before fixation, cells were counted 
and seeded into poly-L-lysine-coated (Sigma-Aldrich; #P4832) µCLEAR bottom 96-well plate 
(Greiner Bio-One; #655087) at a density 75000 cells/100ul full media/well. LCLs were then 
allowed to attach to the surface of the wells for additional 2 hours, fixed for 15 min at room 
temperature (RT), permeabilized in 0.5% Triton X-100 in PBS for 20 min at 4°C. Blocking step 
with heat-inactivated 20% human serum for 15 min in RT was followed by staining with 
primary and secondary antibodies and 4′,6-Diamidino-2-phenylindole dihydrochloride (DAPI; 
#D9542) to visualize nuclei. To detect gamma-H2AX we used mouse monoclonal anti-phospho-
histone H2AX antibody (Millipore; #05-636), for detection of RAD51 a rabbit polyclonal anti-
RAD51 antibody was utilized (Santa Cruz Biotechnology; #sc-8349). Alexa Fluor 488- and Alexa 
Fluor 568-conjugated secondary antibodies from Molecular Probes (Invitrogen; #A-11034 and 
#A-11031, respectively) were used, and fluorescent images were automatically acquired from 
each well of the 96-well plate using an Opera High-Content Screening System (Perkin Elmer). 
Pictures were taken at no saturating conditions using a 40x magnification lens and the 
intensity of gamma-H2AX nuclear signal and the number of RAD51 foci in nuclei were 
calculated. 
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4.2 MTT colorimetric assay 
The effect of PARP inhibition on cell viability was assessed using the MTT colorimetric 
assay. Briefly, 200ul of cellular suspension in full media was plated to each well of 96-well plate 
at the density of 104 cells/well. Cells were then treated with DMSO (control) or PARP inhibitors 
olaparib (concentrations 2, 4, 8 μM) or veliparib (10, 25, 50, 100 μM) for 72 hours under 
standard growth conditions. As LCLs tend to form large aggregates of cells, cells were 
resuspended by pipetting up and down once a day using multichannel pipette in order to 
ensure equal distribution of the treatment to all cells. Adherent breast cancer cell line MDA-
MB-231 did not have to be resuspended by pipetting. 3 days after the beginning of treatment, 
50 ul of MTT dissolved in PBS (stock 5mg/ml MTT) was added onto plate and incubated under 
normal growth conditions for 4 hours. Afterwards, 50 ul of SDS/HCl solution (500ml SDS 10% + 
150µL HCl 37%) was transferred into each well and plates were kept in a cell culture incubator 
for additional 16 hours. Absorbance at 544 nm was read on a spectrophotometer (Victor 3 
Plate Reader; PerkinElmer), the data were then normalized to a mean absorbance detected in 
wells containing media without cells, and the results were expressed as a percentage (%) of 
the control (DMSO-treated cells). 
 
4.3 Colony formation assay 
MDA-MB-231 cells expressing either shScramble or shBRCA1-1 or shBRCA1-5 clone were 
treated with DMSO or with indicated concentration of PARP inhibitor OLP or VLP for 24 hours. 
Afterwards, the cells were seeded at a density of 300 cells/well in 6-well plates and incubated 
under normal growth conditions for 7 days. Medium was removed and cells were washed 
twice with PBS, ﬁxed with ice-cold methanol (Sigma; #32213) for 10 min, and stained with 
0.5% crystal violet solution (made in 25% methanol) for 10–20 min. Crystal violet (Sigma; 
#C3886)  was pour out, plates were rinsed several times with distilled water and allowed to dry 
over night at room temperature. Number of colonies containing more than 50 cells was 
counted. 
 
4.4 Basal PARP enzymatic activity 
The PARP enzymatic activity was determined using the HT Chemiluminescent 
PARP/Apoptosis Assay kit (Trevigen; #4685-096-K) according to the manufacturer’s 
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instructions with several modifications. Eight million exponentially growing cells were washed 
once with ice-cold PBS and lyzed in 100 ul of Trevigen Cell Extraction Buffer (1x I-PAR Assay 
buffer; 0.4 mol/L NaCl, 0.9 % Triton X-100, Complete protease inhibitor cocktail [Roche; 
#11697498001]) on ice for 30 min and periodically vortexed. After centrifugation of the cellular 
lysates at 14,000 rpm at 4°C for 10 min, protein concentration was quantified using DC Protein 
Assay Kit II (Bio-Rad; #500-0112) using BSA as a standard. A basal PARP enzymatic activity was 
determined using the HT Chemiluminescent PARP/Apoptosis Assay kit according to the 
manufacturer’s instructions with several modifications. The cellular lysate (10 μg/well) was 
added in duplicates to the wells of 96-well plate, which contained PARP buffer and PARP 
cocktail, and incubated at room temperature for 1 hour. Activated DNA was added only to the 
standards but not to extracts, which allowed to measure a basal enzymatic activity. The wells 
were washed three times with PBS and 0.1% Triton X-100 (PBS-T) and three times with PBS 
and then incubated with streptavidin horseradish peroxidase, diluted in strep diluent buffer 
1:1000, for 1 hour. The wells were then washed as previously described (3x with PBS-T + 3x 
with PBS). Chemiluminescent detection was performed according to the manufacturer’s 
instructions (EnVision Multilabel Plate Reader; PerkinElmer). The background luminescence 
was subtracted from the readings of the samples and standards served for calculation of PARP 
activity from a standard curve. 
 
4.5 Cellular growth rate calculation 
Differences in the cellular growth rate were determined using the above mentioned MTT 
colorimetric assay with some modifications. From each LCL 104 cells/well/200ul full media 
were plated in hexaplicates into two separate 96-well plates. The first plate was subjected to 
an MTT addition at time 0 hours whereas the MTT solution was added into the second plate 72 
hours later, i.e. the same duration as for determination of sensitivity to PARP inhibitors was 
used to determine growth rate of LCLs. Plates were incubated with the MTT for 4 hours which 
was followed by incubation with SDS/HCl solution for additional 16 hours. Absorbance at 544 
nm was measured on a spectrophotometer and the data were normalized to a mean 
absorbance detected in wells containing media without cells. Growth rate was calculated as a 
ratio between the mean absorbance from 72 hour timepoint and the mean absorbance at 
timepoint 0 hours. 
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4.6 BRCA1 transcriptional activation assay (performed during my short stay at 
the MOFFITT Cancer Center) 
The ability of BRCA1 BRCT domain (WT or mutated) in the presence or absence of PARP 
inhibitor OLP was determined using a highly reproducible assay, transcription activation assay. 
Construct containing WT BRCA1 (amino acids 1396−1863) was used as a positive control and 
deleterious variant M1775R as a negative control (as previously described by Carvalho, Pino et 
al. 2009). HEK293FT cells were seeded in 24-well tissue culture plates in a concentration 5 × 
104 cells/well. 24 hours later, cells were transfected with vectors containing studied BRCA1 
variants in triplicates with Fugene 6 (Promega; #E2691) according to the manufacturer's 
instructions. To mimick the heterozygous status, co-transfection of WT BRCA1 and pFLAG-
CMV3 vector containing the BRCA1 A1708E variant (exons 16–24) and lacking the GAL4 DNA 
binding domain was performed. The vectors containing the variants were co-transfected with 
pG5Luc, which contains a firefly luciferase reporter gene driven by GAL4-responsive binding 
sites, and phGR-TK, which contains a Renilla luciferase gene driven by a constitutive TK basal 
promoter used as an internal control. 24 hours post-transfection, growth medium was 
replaced by a medium containing either DMSO (control) or PARP inhibitor OLP of a final 
concentration 16μM. Cells were harvested 24 hours after the treatment, and luciferase activity 
was measured using the Dual-Luciferase Reporter Assay System (Promega; #E1910) following 
the manufacturer's instructions. Activity was plotted as a percentage of the WT BRCA1 activity 
of DMSO-treated cells. 
 
5 Gene and miRNA expression profiling 
 
5.1 mRNA expression profiling 
Whole-genome transcriptional profiling was performed using Agilent Human Gene 
Expression G3 v2 8x60K Microarrays (Agilent microarray design ID 039494, P/N G4851B). 
Briefly, LCLs were either non-treated or treated with DMSO (control for olaparib-treated cells) 
or PARP inhibitor olaparib (8 µM) for 72 hours and total RNA was then extracted. LCLs 100 ng 
of total RNA was labeled using the Low Input Quick Amp Labeling Kit (Agilent Technologies) 
following manufacturer´s instructions and the One-Color Microarray-Based Gene Expression 
Analysis approach. Labeled samples were purified with silica-based RNeasy spin columns 
(Qiagen) and 600 ng of labeled extract of total volume 50 µl was hybridized at 65°C for 17 
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hours. Images were scanned on a G2505C DNA microarray scanner (Agilent) and data were 
extracted with Feature Extraction software (Agilent; version 10.7). Background correction 
(performed via the normexp method) and between arrays normalization (utilizing the 
quantiles method) was performed using Babelomics 4.3 web tool, which is available at 
http://babelomics.bioinfo.cipf.es. Microarray dataset from non-treated samples have been 
deposited in the Gene Expression Omnibus (GEO) public repository with GSE60396 GEO 
accession number. 
 
5.2 miRNA expression profiling 
miRNA expression profiling was performed using the 7th generation miRCURY LNATM 
microRNA Array kit (Exiqon). Briefly, 300 ng of total RNA, isolated from from non-treated or 
DMSO/8 µM olaparib-treated (for 72 hours) LCLs, was first incubated with CIP and 
subsequently labeled with Hy3 fluorescent dye using the miRCURY LNA™ microRNA Hi-Power 
Labeling Kit (Exiqon). Labeled RNA was then hybridized onto miRNA microarray slides for 16 
hours at 56°C using Agilent SureHyb hybridization chambers and a hybridization oven with 
rotation. After washing and drying steps, the arrays were scanned and the images were 
analyzed using Feature Extraction software (Agilent; version 10.7), using a modified Exiqon 
protocol. The microarray background correction was performed using normexp method and 
normalization between arrays was carried out via quantiles method in R statistical software 
(version 2.13.0). Microarray dataset from non-treated samples is publicly available at the GEO 
public repository (GEO accession number GSE60444). 
 
6 Bioinformatic and statistical analysis 
 
6.1 Microarray data analysis 
Replicate probes from the normalized data were merged by their mean profile and 
mRNAs and miRNAs with low expression variation (VAR<1xE-9 for mRNA profiling; VAR<0.002 
for miRNA data) across samples were excluded. These data pre-processing steps were 
performed using the preP web server application available in the Asterias web server 
(http://asterias.bioinfo.cnio.es/). To identify differentially expressed genes and miRNAs 
between control and mutated LCLs we used POMELO II web tool, which is accessible in the 
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Asterias web server. The estimated significance level (unadjusted P value) was corrected for 
multiple hypotheses testing using Benjamini and Hochberg false discovery rate (FDR) 
adjustment. mRNAs with FDR<0.15 were considered as significantly differentially expressed, 
whereas FDR<0.05 was used as a threshold to select differentially expressed miRNAs. For the 
unsupervised hierarchical clustering analysis, GENE-E software version 3.0.204 was used 
(Broad Institute; http://www.broadinstitute.org/cancer/software/GENE-E/index.html) 
performing one minus Pearson correlation with Average-Linkage clustering method. 
 
6.2 Pathway analysis using IPA 
To annotate DEG and BRCA1 BRCT protein interactors into biological networks and for 
evaluation of their functional significance the Ingenuity Pathway Analysis software package 
was used (IPA; http://www.ingenuity.com). IPA uses the Ingenuity Pathway Knowledge Base, 
which is derived from known functions and interactions of genes published in literature, 
allowing the identification of biological networks, global functions and functional pathways of 
a particular set of data. 
To determine the top canonical pathways, biological functions, and molecule networks 
associated with analyzed datasets (DEG derived from microarray analysis, protein interactors 
obtained using the mass spectrometry approach), a core analysis was performed from which 
the most dramatically affected functions/pathways were extracted (p-value < 0.05). The p-
value, calculated with the right-tailed Fisher´s exact test, estimates the probability that the 
association between the dataset and canonical pathways/biological functions/molecule 
networks might be due to a random chance. 
 
6.3 Integration of miRNA and mRNA gene expression signatures 
As single miRNA can target many mRNAs and, on the contrary, a single mRNA can be 
targeted by multiple miRNAs, we used IPA to identify only those miRNA-mRNA pairs which has 
been previously experimentally validated (using TarBase, miRecords and Ingenuity Expert 
Findings databases). The miRNA and mRNA microarray expression profiles from DMSO/OLP-
treated LCLs were used, in particular the 215 miRNAs, which passed the normalization and pre-
processing step, and the 312 genes, which were differentially expresses between DMSO- and 
OLP-treated WT cells. IPA microRNA Target Filter was then utilized to select only miRNA-mRNA 
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pairs showing anti-correlated expression pattern and to prioritize experimentally validated 
mRNA targets. 
 
6.4 Statistical analysis 
To test the statistical difference between groups of LCLs (when analyzing quantitative RT-
PRC, Western blotting, immunofluorescence experiment, PARP enzymatic activity assay, 
cellular growth rate), independent samples Student´s t-test was used for normally distributed 
variables and Mann-Whitney U test for non-normal data distribution. For analysis of the 
differences in sensitivity of LCLs to OLP and VLP, the cellular growth rate was used as a 
covariate in a linear regression model. To check association between two variables, Pearson or 
Spearman correlation coefficients were calculated for normally or not normally distributed 
data, respectively. P-value lower than 0.05 was considered as statistically significant. 
Calculations were done using SPSS Statistics software (version 17.0; IBM) and dot plots were 
created with GraphPad Prism (version 5.03; GraphPad Software; www.graphpad.com). 
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Taking into account the variability in breast and ovarian cancer incidence and age of onset 
in carriers of BRCA1 mutations, the first objective of this thesis was therefore to explore BRCA1 
haploinsufficiency in cell lines harboring either missense or truncating mutation in this gene by 
checking BRCA1 expression, DNA repair capacity, and comparing gene or miRNA expression 
profiles. 
 
1.1 BRCA1 expression is reduced in carriers of heterozygous truncating mutation 
in BRCA1 
 
To determine whether there were any differences in the level of BRCA1 expression among 
mutation carriers, we compared both BRCA1 mRNA and protein levels in BRCA1 +/- and 
BRCA1 +/+ cells. For this purpose, we established a panel of lymphoblastoid cell lines (LCLs) 
from 15 healthy women carrying heterozygous missense or truncating mutation in BRCA1 and 
6 healthy ancestry-matched controls negative for BRCA1 mutation (Table 4). 
The BRCA1 mRNA level was determined by real-time RT-PCR using BRCA1-specific primers 
that did not distinguish between wildtype and mutant allele, and the expression curves were 
normalized to the expression of housekeeping genes MRLP19 and HPRT1. The average BRCA1 
expression in cells harboring heterozygous mutation was 88.6% of that of control cells derived 
from non-carriers (Figure 8A; P = 0.208). However, when we stratified the mutations according 
to their type (missense versus truncating) we observed a significantly lower BRCA1 expression 
in cells with truncating mutation in comparison to WT cells (Figure 8B; P = 0.028). These results 
are in agreement with the commonly accepted fact that the presence of a premature stop 
codon in mRNA often leads to an activation of a nonsense-mediated mRNA decay (NMD) 
pathway (Conti and Izaurralde 2005). On the other hand, cells harboring missense mutation 
showed comparable level of expression of BRCA1 as control cells (Figure 8B; P = 0.593) and 
significantly higher BRCA1 expression than cells with truncating mutation (Figure 8B; P = 
0.010), suggesting that the mutated transcripts do not undergo degradation by the cellular 
RNA decay machinery. 
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Figure 8. LCLs carrying a monoallelic truncating mutation in BRCA1 show decreased BRCA1 mRNA and 
protein expression. A) Relative BRCA1 expression in 6 WT LCLs and 15 LCLs carrying heterozygous 
mutation. Mutation carriers show 88.6% of the normal BRCA1 expression level in WTs (two-tailed 
Student’s t-test; P = 0.208 with a mean of 1.202 ± 0.08 SEM for WT cells and 1.065 ± 0.06 SEM for 
mutated cells). Means are shown by lines and error bars represent SEM. B) Relative BRCA1 mRNA level 
in 6 WT LCLs, 5 LCLs carrying missense mutation, and 10 LCLs with truncating mutation in BRCA1 (two-
tailed Student’s t-test; P = 0.028 for comparison between WT and truncating LCLs, and P = 0.010 when 
comparing LCLs with missense and truncating mutation; mean of 1.202 ± 0.08 SEM for WT, 1.263 ± 0.08 
SEM for missense LCLs, and 0.967 ± 0.06 SEM for truncating LCLs). C) BRCA1 protein expression in LCLs 
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derived from non-carriers (6 LCLs) and BRCA1 mutation-carriers (15 LCLs) (Mann-Whitney U test; P = 
0.119 with a mean of 2.197 ± 0.55 SEM for WT cells and 1.460 ± 0.30 SEM for mutated cells). Intensity of 
protein bands was quantified by Image-J and normalized to WT sample 10S889-L. D) BRCA1 protein level 
in control LCLs and cells harboring missense or truncating heterozygous mutation (two-tailed Student’s 
t-test; P = 0.047 with a mean of 2.197 ± 0.55 SEM for WT and 1.065 ± 0.24 SEM for truncating LCLs). E) 
Western blot analysis of BRCA1 expression in a panel of LCLs. Full-length BRCA1 was detected using a 
monoclonal anti-BRCA1 antibody (Calbiochem, #OP92) and HSC70/HSP70 served as a loading control. 
First sample in each blot is identical (WT cell line 10S889-L) and served for between blots-normalization 
when analyzing protein band densities by ImageJ. * indicates LCLs which could not be included in the 
final panel of analyzed cell lines. 
 
 
In order to check the BRCA1 protein level and the stability of mutated protein, we 
performed a Western blotting of the nuclear protein fraction of LCLs (Western blot scan shown 
in Figure 8E). Using an anti-BRCA1 antibody with an epitop against N-terminus of the protein 
we observed that LCLs harboring monoallelic BRCA1 mutation show 66.5% of the WT protein 
level (Figure 8C; P = 0.199). As in the case of mRNA, the division of LCLs based on their 
mutation type allowed us to detect a significantly less full-size BRCA1 (~250 kDa) in cells with 
truncating mutation than in control cells (Figure 8D; P = 0.047). Interestingly, we observed 
comparable full-size BRCA1 protein level in cells harboring monoallelic missense mutation 
when compared to control cells (Figure 8D; P = 0.952), suggesting that, although altered, the 
proteins are stable. 
It has been reported in previous studies that BRCA1 is present in cells as heterogeneous 
species, depending on its phosphorylation status, and various sets of Ser residues are being 
phosphorylated throughout the cell cycle and in response to DNA damage (Thomas, Smith et 
al. 1997; Okada and Ouchi 2003). We were able to distinguish a hypo- and hyper-
phosphorylated form of BRCA1 in our Western blots. As in the case of a total BRCA1 protein 
level, there were no statistically significant differences in the level of hypo- or hyper-
phosphorylated protein between mutated and control cells (Figure 9A; P = 0.057, and Figure 
9B; P = 0.399, respectively). However, the stratification of samples according to the BRCA1 
mutation type once again showed that cells with truncating mutation expressed significantly 
less hypo-phosphorylated form of BRCA1 than control cells (Figure 7C; P = 0.029). In addition, 
the level of hypo-phosphorylated BRCA1 correlated with the BRCA1 gene expression (Figure 
10). 
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Interestingly, an evaluation of the ratio of hyper-P/hypo-P BRCA1 revealed that control 
cells contained a higher level of hypo-P BRCA1 than the phosphorylated form (hyper/hypo-P 
ratio of 0.938) whilst cells harboring either of the BRCA1 mutation type contained almost 2.2-
times more phosphorylated protein form than hypo-P BRCA1 (Figure 9D; P = 0.005). Even 
though the cells with missense  mutations showed elevated hyper-P/hypo-P BRCA1 ratio, the 
variability among these samples did not allow to reach significance when compared with 
control cells (Figure 9E; P = 0.168). However, we again observed a significant difference 
between cells with truncating mutation and control cells (Figure 9E; P = 0.001). 
Finally, we checked the stability of potentially presented truncated proteins which should 
avoid the NMD by triggering translation re-initiation, which has been described for the 
c.68_69delAG mutation (Buisson, Anczukow et al. 2006), but we were unable to detect any 
truncated BRCA1 protein in this particular LCL. 
 
 
Figure 9. Differences in the proportion of hypo-/hyper-phosphorylated form of BRCA1 protein 
between WT and mutated LCLs. A) Relative protein level of hypo-P BRCA1 in 6 WT LCLs and 15 LCLs 
with heterozygous mutation. Mutated LCLs show 70% of the protein level of WTs (Mann-Whitney U test; 
P = 0.057 with a mean of 1.838 ± 0.50 SEM for WT cells and 1.288 ± 0.37 SEM for mutated cells). Means 
are demonstrated by lines and error bars represent SEM values. Band intensities were measure using 
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Image-J and normalized to expression of WT sample 10S889-L. B) Relative expression of hyper-P BRCA1 
in WT and mutated LCLs. Mutated LCLs show 126% of the protein level detected in WTs (two-tailed 
Student’s t-test; P = 0.399 with a mean of 1.627 ± 0.39 SEM for WT cells and 2.054 ± 0.27 SEM for 
mutated cells). C) Comparison of the levels of hypo-P BRCA1 between 6 WT, 5 missense, and 10 
truncating LCLs (two-tailed Student’s t-test; P = 0.029 with a mean of 1.838 ± 0.50 SEM for WT and 0.855 
± 0.11 SEM for truncating LCLs). D) Normalized ratio of hyper-P and hypo-P form of BRCA1 in LCLs 
derived from non-carriers (6) and BRCA1 mutation-carriers (15) (Mann-Whitney U test; P = 0.005 with a 
mean of 0.938 ± 0.16 SEM for WT cells and 2.227 ± 0.33 SEM for mutated cells). E) Hyper-P/hypo-P 
normalized BRCA1 ratio in 6 WT LCLs, 5 LCLs carrying missense mutation and 10 LCLs with truncating 
mutation in BRCA1 (Mann-Whitney U test; P = 0.001 with a mean of 0.938 ± 0.16 SEM for WT and 2.300 
± 0.32 SEM for truncating LCLs). 
 
 
Figure 10. Correlation between mRNA and hypo-P BRCA1 protein levels. Significant positive Spearman 
correlation between gene and protein expression in panel of LCLs. WTs are represented by light grey 
dots (○), LCLs with missense mutation are shown as grey squares (□), and cell lines carrying truncating 
mutation are displayed as black triangles (∆). 
 
 
1.2 LCLs derived from BRCA1 mutation carriers show elevated levels of gamma-
H2AX and impaired RAD51 foci formation 
 
BRCA1 plays an important role in multiple repair pathways, including single-strand 
annealing and the repair of DNA double-strand breaks (DSBs) by homologous recombination 
(HR) or non-homologous end joining (NHEJ) (Roy, Chun et al. 2011). As we detected differences 
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in BRCA1 mRNA and protein levels, depending on the mutation status of LCLs, we 
hypothesized that mutated cells could be haploinsufficient for the DNA repair under basal 
conditions. To test this hypothesis we performed a high-throughput screening of the intensity 
of gamma-H2AX signal (commonly used as a marker of DNA damage, especially DSBs) and the 
number of RAD51 foci (protein assisting in the repair of DSBs) in nuclei of either non-irradiated 
or 10 Gy-irradiated cells. 
Monitoring gamma-H2AX signal by high content confocal microscope revealed that, even 
under basal conditions, LCLs harboring mutated BRCA1 accumulated significantly more DNA 
damage than control cells (Figure 11A, Figure 11C; P=0.027) and significantly lower number of 
RAD51 foci per nucleus (Figure 11B, Figure 11C; P=0.020). 
As expected, 10 Gy irradiation increased the intensity of the gamma-H2AX nuclear signal 
in both control and mutated cells, but the level of DNA damage was significantly elevated in 
LCLs with BRCA1 mutations (Figure 11A; P<0.001). No significant difference in the number of 
RAD51 foci after 10 Gy irradiation was observed between control and mutated cells (Figure 
11B; P=0.253). 
In order to confirm our observation, we analyzed a double amount of nuclei (240) in a 
replicated experiment and we detected even more significant evidence of increased DNA 
damage and decreased number of RAD51 foci in non-irradiated mutated LCLs (data not shown; 
P<0.001 for both gamma-H2AX signal intensity and number of RAD51 foci). However, we were 
not able to replicate the significant differences in DNA damage and repair after IR. 
Surprisingly, stratification of LCLs according to their BRCA1 mutation status revealed that 
cells harboring truncating mutation present significantly increased level of DNA damage under 
basal conditions when compared to either WT cells or cells with missense mutation (Figure 
11C, Supplementary Figure S1A; P<0.001). The number of RAD51 foci per nuclei in non-
irradiated cells was, however, significantly decreased in cells harboring either of the BRCA1 
mutation type (Figure 11C, Supplementary Figure S1B; P<0.001). 
In order to test if the differences in number of RAD51 foci between groups of non-treated 
LCLs resulted from changes in RAD51 protein levels, a Western blot analysis of whole cell 
lysates was performed. As shown in Figures 12A and 12B, there were no statistically significant 
differences in RAD51 protein levels between groups of LCLs, indicating that the changes in 
RAD51 foci formation under basal conditions are not associated with a corresponding change 
in the cellular level of RAD51 protein, and that BRCA1 haploinsufficiency in mutated LCLs leads 
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to an impairment of RAD51 redistribution to nuclear foci rather than to a failure to express 
normal levels of the protein. 
 
 
Figure 11. Effect of the BRCA1 germline mutation and IR on the level of DNA damage and repair. A) 
High-throughput microscopy quantification of gamma-H2AX signal intensity in nuclei of WT LCLs or cells 
with mutated BRCA1 which were either non-treated or irradiated with 10 Gy. The data represent a 
signal intensity detected in 120 individual nuclei of each LCL in the group and the grey line indicates 
mean intensity of the gamma-H2AX signal. The differences between groups were evaluated using Mann-
Whitney U test (* represents P<0.05 and *** signifies P<0.001). B) Average number of RAD51 foci per 
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nucleus in control or mutated cells either non-irradiated or exposed to 10 Gy. The data represent a 
mean from 120 analyzed nuclei of each LCL in the particular group +/- SEM. The P-value was calculated 
using Mann-Whitney U test (* represents P<0.05). C) Representative immunofluorescence images of 
non-irradiated cell lines harboring WT BRCA1 (10S889-L) or heterozygous missense (11S65-L) or 
truncating (09S798-L) mutation. Each column consists of the same field of view using DAPI to visualize 
nuclei, mouse monoclonal anti-phospho-histone H2AX antibody to detect gamma-H2AX, and rabbit 
polyclonal anti-RAD51 antibody to detect RAD51 foci. 
 
 
 
Figure 12. BRCA1 is not required for maintaining normal RAD51 protein levels in LCLs. A) Western blot 
analysis of RAD51 expression in a panel of LCLs (WT, MIS = missense, TRUN = truncating). RAD51 was 
detected using a rabbit polyclonal anti-RAD51 antibody (Santa Cruz; #sc-8349) and β-actin served as a 
loading control. First sample in both blots is identical (WT cell line 06S179-L) and served for between 
blots-normalization when analyzing protein band densities by ImageJ. * indicates LCLs which could not 
be included in the final panel of analyzed cell lines. B) RAD51 protein level in control LCLs and cells 
harboring missense (MIS) or truncating (TRUN) heterozygous mutation (two-tailed Student’s t-test; no 
significant differences between groups; mean of 1.390 ± 0.24 SEM for WT, 1.408 ± 0.12 SEM for MIS, 
and 1.509 ± 0.12 SEM for TRUN). Intensity of protein bands was quantified by Image-J and normalized to 
WT sample 06S179-L. 
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1.3 Gene expression profiles vary depending on the BRCA1 mutation status 
 
Taking into account the dramatic elevation of lifetime risk of breast cancer development 
in BRCA1 mutation carriers, we aimed to investigate whether such increased risk could be 
connected with changes in gene expression profiles in cells harboring either missense or 
truncating monoallelic mutations. 
Unsupervised hierarchical clustering did not provide a clear splitting of the samples 
according to their mutation type, reflecting their similarity in gene expression profiles (Figure 
13). However, we observed a tendency of separate clustering between cells harboring 
missense mutation (highlighted in red) and the rest. 
 
 
Figure 13. Unsupervised hierarchical clustering of LCLs harboring WT BRCA1 or heterozygous missense 
or truncating mutation. Dendrograms derived from unsupervised hierarchical clustering based on 
expression of 42807 transcripts that remained after normalization and pre-processing. Color labels 
define particular BRCA1 mutation status: WTs in blue, missense highlighted in red, and truncating 
represented by black color. The cluster tree shows relations of particular samples to each other. 
 
We then compared expression profiles of controls with those of individuals with missense 
or truncating mutations, aiming to identify differentially expressed genes (FDR < 5% or logFC > 
2 in absolute value). By comparing the set of 42807 transcripts which passed the normalization 
and pre-processing data transformation steps, we were able to identify a set of genes whose 
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expression was significantly up- or down-regulated between studied groups of samples (Figure 
14A). Interestingly, the highest number of differentially expressed genes was observed when 
comparing control samples with cells harboring missense mutation (Figures 14A and 14B), 
indicating that their expression profiles are the most distinct from all other comparisons which 
is in agreement with the trend observed in unsupervised hierarchical clustering (Figure 13). 
The annotated genes which differentiated between specific groups are listed in Table 5 and 
their differential expression is shown in a heatmap in Figure 14C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Differentially expressed transcripts/genes between groups of LCLs depending on their 
BRCA1 mutation status. A) T-test with 20022 permutations was used in order to obtain genes that 
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differed between LCLs. The graph shows a comparison of the number of differentially expressed 
transcripts with logFC > |2| between WT, missense (MIS), truncating (TRUN) and mutated (MUT = MIS + 
TRUN) LCLs. B) Venn diagram illustrating the number of genes being differentially expressed (logFC > 
|2|) between: WT vs MIS, WT vs TRUN and MIS vs TRUN. For each comparison, the overlap of genes is 
shown. The numbers highlighted in red are up- or down-regulated genes that are specific for particular 
comparison. C) Gene expression patterns of 20 genes differentiating LCLs depending on their BRCA1 
mutation status. LCLs and their BRCA1 mutation status are indicated at the top of the figure. The mean 
values of normalized and pre-processed probe intensities are visualized in the heat map. Probe 
intensities above and below the global value are denoted by shades of red and blue, respectively, and 
those at the global mean level are shown in white. Up- or down-regulated genes in a group of LCLs (in 
bold) from particular comparison are marked with a red and blue arrow, respectively. 
 
 
Table 5. Description of the 20 genes that differentiate groups of LCLs depending on the type of BRCA1 
mutation. 
Comparison Gene symbol
1 
Gene name Chromosome logFC 
Down-
regulated 
in 
WT vs MIS 
ADCY1 adenylate cyclase 1 (brain) 7  2.07 WT 
PLS3 plastin 3 X  2.32 WT 
IFNG
# interferon, gamma 12 -2.00 MIS 
TSPAN5 tetraspanin 5 4 -2.02 MIS 
L1TD1 LINE-1 type transposase domain containing 1 1 -2.05 MIS 
IRF5
#
 interferon regulatory factor 5 7 -2.13 MIS 
ICOS
#
 inducible T-cell co-stimulator 2 -2.13 MIS 
PPARG peroxisome proliferator-activated receptor gamma 5 -2.15 MIS 
ITGB5
#
 integrin, beta 5 3 -2.17 MIS 
PLXDC2 plexin domain containing 2 10 -2.26 MIS 
WNT11 wingless-type MMTV integration site family, member 11 11 -2.51 MIS 
DDX43 DEAD (Asp-Glu-Ala-Asp) box polypeptide 43 6 -2.55 MIS 
CLLU1OS 
chronic lymphocytic leukemia up-regulated 1 opposite 
strand 
12 -2.81 MIS 
WT vs TRUN 
LY6D lymphocyte antigen 6 complex, locus D 8 -2.04 TRUN 
MMP7 matrix metallopeptidase 7 (matrilysin, uterine) 11 -2.14 TRUN 
MIS vs TRUN 
SEPT10 septin 10 2  2.01 TRUN 
RNF130 ring finger protein 130 5  2.22 TRUN 
TNK1 tyrosine kinase, non-receptor, 1 17 -2.09 MIS 
RAMP1 receptor (G protein-coupled) activity modifying protein 1 2 -2.14 MIS 
GALNT14 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 14 (GalNAc-T14) 
2 -2.98 MIS 
NOTE: logFC, logarithmic fold change. Only differentially expressed genes with logFC > |2| are shown in the table. 
agenes involved in immune response (according to the Reactome_Immune_system gene set) are marked with # 
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1.4 Haploinsufficiency in BRCA1 leads to a defective expression of genes involved 
in immune response and cancer 
 
In order to get more insight into the consequences and biological relevance of differential 
gene expression between groups of LCLs, we used Ingenuity Pathway Analysis (IPA) software 
and investigated molecular/cell function alterations and interaction networks of differentially 
expressed genes. 
Genes, which were differentially expressed in cells with heterozygous missense mutation 
when compared to WTs, regulate 26 molecular and cellular functions (Supplementary Table 
S2). Among the top five altered biological functions, most of them are known to be relevant for 
cancer development (Figure 15A). Then we subjected the list of 13 differentially expressed 
genes to IPA gene network analysis in order to generate interaction network and calculate a 
probability score. 10 out of 13 input genes were included into a network consisting of 34 
molecules (Figure 15B) and displaying a probability score of 25 (score = 25 represents p-value = 
10-25). In addition, BRCA1 was artificially added in order to visualize its possible interactions 
with the network, and was found to be both directly (through TNF) and indirectly (via NFκB 
complex) associated with the pathway. 
Interestingly, the members of this pathway were found to be significantly associated with 
many diseases and functions, mainly immune and inflammatory responses, cellular 
development, cell signaling, cellular proliferation, cell death and survival etc. Visualization of 
the involvement of the network members in cell death (6 out of the set of 13 differentially 
expressed genes involved; p = 2.32 x 10-5) and inflammatory response (2/13 differentially 
expressed genes implicated; p = 1.32 x 10-6) pathways is shown in Supplementary Fig. S2. 
We performed a similar analysis for the two differentially expressed genes in cells 
harboring heterozygous truncating mutation and found that they are involved in regulation of 
8 molecular and cellular pathways (Supplementary Table S3), including cellular movement, 
development, proliferation, interaction, cell death etc. The IPA gene network analysis did not 
provide any signs of interaction between MMP7 and LY6D, the two differentially expressed 
genes in cells carrying truncating mutation in BRCA1 gene, in a common network. 
 
 
91 
 
 
Figure 15. Downstream effect analysis and network of differentially expressed genes between WTs 
and cells with BRCA1 missense mutation. A) Top 5 molecular and cellular functions significantly 
associated with genes differentially expressed in cells harboring heterozygous missense mutation in 
BRCA1. The grey line represents a significance threshold (P-value 0.05). B) IPA-based network of 
differentially expressed genes (underlined) between WTs and cells with BRCA1 missense mutation. 12 
differentially expressed genes were input into the analysis, 10 of them (underlined) are represented in 
the 34 molecule output pathway. The legend specifies the molecule type, type of interaction and up-
/down-regulation of differentially expressed genes. 
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1.5 No alteration of miRNA expression found in cells carrying monoallelic BRCA1 
mutation 
 
Changes in expression of microRNAs (miRNAs) have been found to be associated with 
breast cancer development, metastasis, prognosis and response to treatment (Mulrane, 
McGee et al. 2013). In addition to gene expression profiling, we also aimed to investigate 
whether cells derived from BRCA1 mutation carriers show deregulated miRNA expression. 
miRNA expression profiles showed a high similarity between WT LCLs and cells harboring 
heterozygous mutation in BRCA1. There were no significantly differentially expressed miRNAs 
between groups of LCLs with FDR<0.05 or logFC > 2 in absolute value. The list of differentially 
expressed miRNAs passing the threshold of unadjusted P-value <0.05 is shown in 
Supplementary Fig. S3. 
 
 
 
RESULTS 
Part II
94 
 
  
95 
 
The second objective of this work was to investigate whether there are any differences in 
response of LCLs to various PARP inhibitors, depending on their BRCA1 mutation status. In 
addition, we aimed to look at factors which could potentially influence the response of cells to 
PARP inhibitors, including PARP1 expression, its enzymatic activity and cellular growth rate. 
 
 
2.1 BRCA1 knockdown sensitizes the breast cancer cell line MDA-MB-231 to PARP 
inhibition, confirming a synthetic lethal interaction between BRCA1 and PARP1 
 
In order to confirm the synthetic lethal interaction between BRCA1 and PARP1, BRCA1 
was silenced using a set of six short hairpin RNAs (shRNAs) in the BRCA1-proficient breast 
cancer cell line MDA-MB-231 and the ability to form colonies and changes in proliferation in 
response to PARP inhibitors olaparib (OLP) or veliparib (VLP) was evaluated in these cells. 
Western blotting analysis of nuclear proteins revealed a substantial variability in the silencing 
ability between particular shRNAs (Figure 16A). Only shBRCA1-1 (sh1) and shRBCA1-5 (sh5), 
which decreased the level of full-length BRCA1 protein the most, were used for further 
experiments and their effect was compared to the effect of control non-targeting shRNA 
(shScramble). The quantitative RT-PCR confirmed a lower BRCA1 mRNA level in cells expressing 
sh1 and sh5 when compared to shScramble (Figure 16B), confirming the silencing ability of 
these shRNAs at both mRNA and protein level. 
BRCA1 knockdown itself dramatically decreased the number of colonies that the cells 
were able to form 7 days after plating, to 10% (sh1) or 69% (sh5) of the colony quantity found 
in control cells. As expected, both OLP and VLP further altered the ability of sh1 and sh5 cells 
to form colonies (Figure 17A). Consistently with these results, treatment with PARP inhibitors 
also markedly decreased proliferation of cells with silenced BRCA1 when compared to a mild 
effect on the proliferation of control cells (Figure 17B). In addition, the concentration range of 
PARP inhibitors used in these experiments showed that OLP acts synthetically lethal with 
BRCA1 at a lower concentration than VLP. Such confirmation of a synthetic lethal interaction 
between BRCA1 and PARP1 provided a confidence to use these two agents in further 
experiments with our panel of LCLs. 
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Figure 16. BRCA1 silencing ability of a set of human GIPZ lentiviral shRNAmir. A) Western blot analysis 
of BRCA1 protein expression in MDA-MB-231 cells, parental or transduced with 6 BRCA1-specific shRNA 
clones (sh1–6) or control shRNA (shScramble). Nucleolin was used as a loading control for nuclear 
proteins. B) Relative BRCA1 mRNA expression in cells overexpressing non-targeting shRNA or BRCA1-
specific sh1 or sh5. 
 
 
Figure 17. Effect of BRCA1 depletion on sensitivity of MDA-MB-231 cells to PARP inhibitors. A) Colony 
formation assay of control or BRCA1-depleted cells pre-treated either with DMSO (control) or with 
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indicated concentrations of olaparib (OLP) or veliparib (VLP). Values represent a mean and standard 
deviation of 6 replicates. Concentrations of PARP inhibitors are indicated in μM. Compact group of more 
than 50 cells was considered as a colony. B) MTT assay displaying proliferation changes of control or 
BRCA1-depleted cells after treatment with OLP or VLP for 72 hours. A representative example of one of 
two independent experiments is shown. 
 
 
2.2 Carriers of heterozygous truncating mutation in BRCA1 show reduced 
expression of PARP1 
 
As we aimed to investigate the response of LCLs to PARP inhibitors, we first checked the 
gene and protein expression of PARP1 and its enzymatic activity, factors which could 
potentially influence the response of cells to PARP inhibitors. 
The PARP1 gene expression was determined by quantitative RT-PCR and the expression 
curves were normalized to the expression of housekeeping genes MRLP19 and HPRT1. 
Interestingly, we observed a significant decrease in PARP1 expression in cells harboring 
truncating mutation in BRCA1 (Figure 18A; P = 0.028), the same cells which showed lower 
expression of the BRCA1 gene (Figures 8B and 8D). Western blotting analysis of whole cell 
lysates revealed a significant positive correlation between PARP1 mRNA and protein 
expression (Figure 18B; P = 0.027). Similarly as in the case of PARP1 gene expression, cells 
harboring truncating mutations in BRCA1 showed decreased levels of PARP1 protein, however 
the variability between cell lines did not allow to reach statistical significance (Figure 18C; P = 
0.073). Interestingly, unlike cells carrying truncating mutation, cells harboring missense 
mutation in BRCA1 showed comparable PARP1 protein level as WTs. 
In order to check whether the decrease in PARP1 mRNA level is related to an alteration of 
BRCA1 expression, we measured its expression in MDA-MB-231 cells where the BRCA1 gene 
was knocked down by sh1. BRCA1 silencing led to a decrease of PARP1 mRNA levels (of about 
18% when compared to control cells) (Figure 18D), indicating that BRCA1 could be involved in 
regulation of PARP1 gene expression. 
98 
 
 
Figure 18. PARP1 expression in LCLs and MDA-MB-231 cells with depleted BRCA1. A) Relative PARP1 
mRNA level in 6 WT LCLs, 5 LCLs carrying missense mutation, and 10 LCLs with truncating mutation in 
BRCA1 (two-tailed Student’s t-test; P = 0.028 for comparison between WT and truncating LCLs; mean of 
1.270 ± 0.05 SEM for WT, 1.151 ± 0.05 SEM for missense LCLs, and 1.081 ± 0.05 SEM for truncating 
LCLs). B) Significant positive Pearson correlation between PARP1 mRNA and protein levels in a panel of 
LCLs. C) PARP1 protein level in control LCLs and cells harboring missense or truncating heterozygous 
mutation in BRCA1 gene (two-tailed Student’s t-test; P = 0.073 for comparison between WT and 
truncating LCLs; mean of 1.569 ± 0.18 SEM for WT, 1.482 ± 0.26 SEM for missense LCLs, and 1.129 ± 0.14 
SEM for truncating LCLs). D) Relative PARP1 mRNA expression in cells overexpressing non-targeting 
shRNA or BRCA1-specific sh1. E) Western blot analysis of PARP1 expression in a panel of LCLs. Full-length 
PARP1 (116 kDa) and the large fragment of cleaved PARP1 (89 kDa) were detected using anti-PARP1 
antibody (Cell Signaling; #9542) and β-actin served as a loading control. First sample in each blot is 
identical (WT cell line 09S179-L) and served for between blots-normalization when analyzing protein 
band densities by ImageJ. * indicates LCLs which could not be included in the final panel of analyzed cell 
lines. 
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Since it has been previously demonstrated that PARP1 expression and protein level only 
partially correlate with its enzymatic activity (Zaremba, Ketzer et al. 2009; Zaremba, Thomas et 
al. 2011), we decided to check PARP enzymatic activity in our panel of LCLs using two distinct 
methods. Firstly, we measured the level of PAR (poly ADP-ribose), which is a post-translational 
modification that the family of PARP proteins transfers to itself and to other target proteins 
(Ame, Spenlehauer et al. 2004). Using an anti-PAR antibody and Western blot technique, we 
did not find any statistically significant differences in the cellular level of PAR polymers 
between groups of LCLs (Figure 19A), confirming the lack of correlation between PARP1 
expression and enzymatic activity. However, there was markedly higher variability in PAR 
levels in BRCA1 mutated cells than in WTs. In order to measure the enzymatic activity more 
precisely, we used a modified in vitro PARP activity assay which allowed us to determine a 
basal PARP activity in cell lysates (i.e. non-induced naturally activated PARP present in LCLs). 
Using this assay, we did not find any statistically significant differences in basal PARP activity 
between groups of LCLs depending on their BRCA1 mutation status (Figure 19B). Nevertheless, 
results from both experiments indicate that cells harboring heterozygous missense mutation in 
BRCA1 show slightly elevated PARP activity than cells with truncating mutation (Figures 19A 
and 19B). 
 
 
Figure 19. PARP enzymatic activity in LCLs. A) Relative PAR polymer levels in whole cell lysates isolated 
from from 6 WT LCLs, 5 LCLs carrying missense mutation, and 10 LCLs with truncating mutation in 
BRCA1. PAR was detected by Western blot using anti-PAR antibody. Median of the data is represented 
by the line inside the box plots (median of 1.74 ± 0.15 SEM for WT, 1.76 ± 0.30 SEM for missense LCLs, 
and 1.49 ± 0.22 SEM for truncating LCLs). B) PARP activity in the cellular extracts of LCLs measured as 
the amount of ribosylation on histone-coated plates. Line inside of the box plot indicate median of the 
data (median of 32.48 ± 2.95 SEM for WT, 35.33 ± 2.15 SEM for missense LCLs, and 33.42 ± 1.67 SEM for 
truncating LCLs). Graph shows representative results from one out of three independent experiments. 
100 
 
2.3 LCLs harboring heterozygous missense mutations in BRCA1 BRCT domain are 
more sensitive to PARP inhibition than WTs or cells with truncating mutations 
 
Taking into account the different levels of both BRCA1 and PARP1 expression between 
groups of LCLs, we were wondering whether cells carrying various types of BRCA1 mutation 
display different sensitivity to PARP inhibitors OLP and VLP. Indeed, our results with PARP 
inhibitor OLP showed significantly increased sensitivity of cells derived from mutation carriers 
harboring missense mutation in BRCA1 (Figure 20A).  Interestingly, LCLs with truncating 
mutations showed comparable low sensitivity levels to OLP as WT cells. Moreover, the PARP1 
enzymatic activity, measured by an in vitro assay, negatively correlated with viability of the 
cells after treatment with low concentration of OLP (Figure 20C), being in line with previously 
published results (Gottipati, Vischioni et al. 2010). No association between sensitivity of cells 
to OLP and BRCA1 or PARP1 expression was found, indicating that expression levels of these 
two proteins do not play a role in regulation of response to this agent. 
 
Figure 20. Effect of BRCA1 germline mutation on sensitivity of LCLs to PARP inhibitors. A) MTT assay 
displaying proliferation changes of LCLs treated with indicated concentrations of PARP inhibitor OLP for 
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72 hours, relative to control cells (treated with DMSO). 6 WT LCLs, 5 LCLs carrying missense mutation, 
and 10 LCLs with truncating mutation in BRCA1 were used in this experiment. Values represent a mean 
and standard deviation of viabilities of all LCLs belonging to one group, obtained in 3 independent 
experiments. P-values were calculated using a linear regression model taking into account the cellular 
growth rate as a covariate. B) MTT assay of LCLs treated with indicated concentrations of VLP for 72 
hours, relative to control DMSO-treated cells. 6 WT LCLs, 5 LCLs carrying missense mutation, and 10 LCLs 
with truncating mutation in BRCA1 were used in this experiment. Values represent a mean and standard 
deviation of viabilities of all LCLs belonging to one group, obtained in 3 independent experiments. P-
values were calculated using a linear regression model taking into account the cellular growth rate as a 
covariate. C) Significant negative Pearson correlation between PARP enzymatic activity and viability of 
LCLs treated with PARP inhibitor OLP 4μM. 
 
 
Experiments with VLP, the second PARP inhibitor, revealed that higher concentration of 
the reagent had to be used in order to reach 50% inhibition of viability. As in the case of OLP 
treatment, WT cells were the most resistant to VLP treatment (Figure 20B). However, cells 
harboring either of the BRCA1 mutation type, and not only missense mutation, showed 
significantly increased sensitivity to higher concentrations of VLP. 
It is a commonly accepted fact that rapidly dividing cells are more sensitive to DNA 
damaging agents, such as chemotherapeutic drugs (Stark, Zhang et al. 2010). Therefore, we 
raised a question of whether cellular growth rate could act as a cofounding variable, 
influencing sensitivity of LCLs to PARP inhibitors. As shown in Figure 21A, there were no 
significant differences in growth rate between groups of LCLs depending on their BRCA1 
mutation status. However, we indeed found a significant negative correlation between cellular 
growth rate and viability of cells after treatment with the highest concentration of OLP or VLP 
(Figures 21B, 21C). Because of this relationship, growth rate was taken into account as a 
cofounding variable while performing the statistical analysis of cellular response to OLP and 
VLP (P-values mentioned in Figures 20A and 20B). However, the significant differences in 
response of mutated cells to OLP or VLP were still present after incorporating the cellular 
growth rate as a covariate, indicating a growth rate-independent variability in cellular 
sensitivity to OLP and VLP. 
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Figure 21. Cellular growth rate in LCLs and its effect on sensitivity of cells to PARP inhibitors. A)  
Growth rate of 6 WT LCLs, 5 LCLs carrying missense mutation, and 10 LCLs with truncating mutation in 
BRCA1 (mean of 3.988 ± 0.32 SEM for WT, 4.896 ± 1.10 SEM for missense LCLs, and 4.260 ± 0.40 SEM for 
truncating LCLs). Cellular proliferation was measured using modified MTT assay, comparing absorbances 
(544nm) taken at timepoints 0 hours and 72 hours. B) Significant negative Spearman correlation 
between cellular growth rate and viability of LCLs treated with PARP inhibitor OLP 8μM. C) Significant 
negative Spearman correlation between cellular growth rate and viability of LCLs treated with PARP 
inhibitor VLP 100μM. 
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The final part of the thesis was focused on an exploration of the mechanism underlying 
the increased sensitivity of cells with BRCA1 missense mutation to PARP inhibitor OLP. We 
were particularly interested whether the missense mutant could act in a dominant negative 
manner in heterozygous cells. To gain better understanding of the molecular mechanisms 
behind OLP action, we performed studies focusing on the BRCT domain of BRCA1 protein 
(transcriptional activation assay, analysis of BRCT-protein interactions by tandem affinity 
purification coupled to mass spectrometry), where both of the studied missense mutations are 
located. Moreover, profiling of miRNA and gene expression in OLP-treated cells was performed 
in order to select candidate genes involved in the response of cells to this treatment. Finally, 
an integration of the data from gene and miRNA expression was carried out. 
 
 
3.1 Transcriptional activation function of the BRCA1 BRCT domain is not involved 
in the response of cells to OLP 
 
BRCA1 has been found to be involved in several crucial cellular processes, including 
regulation of transcription of other genes through its BRCT domains (Monteiro, August et al. 
1996). As the two deleterious missense mutations present in our panel of LCLs are located in 
the BRCA1 BRCT domain, we hypothesized that the increased sensitivity of these cells to OLP is 
caused, at least partially, by alteration of this function. Using a well described cell-based 
transcriptional assay (Monteiro, August et al. 1996) we analyzed the transcriptional activity of 
constructs containing WT BRCA1 (positive control), missense variants M1775R (negative 
control), G1706E, A1708E, and combination of WT+A1708E in the HEK293FT cellular model 
(Figures 22A and 22B). The co-transfection of WT and A1708E constructs mimicked the 
heterozygous status present in our LCLs and allowed us to test a possible dominant-negative 
effect of the mutated variant on the WT protein function. 
Western blot analysis confirmed an overexpression of all transfected BRCA1 constructs in 
both DMSO- and OLP-treated HEK293FT cells (Figure 22C). As expected, WT BRCA1 was able to 
activate transcription of the reporter gene (Figure 22D). The negative control, as well as both 
tested missense variants (G1706E, A1708E), displayed an altered ability to transcribe the 
luciferase gene, which is in agreement with previously published studies (Lee, Green et al. 
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2010). Interestingly, a co-transfection of constructs containing WT and A1708E variants of 
BRCA1 led to an transcriptional activation which was comparable to the one induced by WT 
construct alone, indicating that the A1708E variant does not act in a dominant-negative 
manner to a WT BRCA1 transcriptional activation function. In was also interesting the note that 
the treatment with PARP inhibitor OLP slightly decreased the ability of WT BRCA1 to activate 
the transcription of the target gene (82% of the WT). 
 
 
Figure 22. Functional analysis of missense variants in BRCA1. A) Diagram of construct visualizing BRCA1 
missense variants tested in this experiment. Grey boxes indicate the DNA binding domain (DBD) of 
GAL4, and the N- and C-terminal BRCT domains. B) Diagram of the five GAL4 DNA binding sites located 
upstream of the luciferase reporter gene. Adapted from Carvalho et al., 2009. C) Transfection efficiency 
was confirmed by Western blot using anti-GAL4-DBD antibody. High levels of a specific antibody and an 
overabundance of the overexpressed protein caused intense localized signals and, consequently, white 
bands at exposed film. D) Quantitative transcriptional assay in HEK293FT cells treated with DMSO 
(control) or OLP for 24 hours. Results are displayed as a percentage of DMSO-treated cells 
overexpressing WT construct, the error bars represent standard deviation from triplicates. The graph 
shows results from one out of three independent experiments. 
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3.2 OLP induces changes in BRCA1 BRCT protein interactors and phosphorylation 
of threonine residue at position 1834 
 
To further investigate whether OLP treatment influences functions mediated by the 
BRCA1 BRCT domain, we decided to analyze BRCT-mediated protein interactions, examined 
whether they are modulated by PARP inhibition and checked which molecular functions are 
the protein interactors involved in. For this purpose, we used HEK293FT cells overexpressing 
the BRCA1 BRCT domain, which was either WT or carrying the G1706E variant, and treated 
them either with DMSO (control) or OLP (16μM). We then analyzed BRCT-bound protein 
complexes by tandem affinity purification coupled with mass spectrometry (TAP-MS) (detailed 
protocol in the Materials and Methods chapter). 
As shown in Figure 23A of a Coomassie stain, we were unable to overexpress the mutated 
BRCT at levels sufficient for further mass spectrometry analysis, even after several rounds of 
transfection optimizations. Thus, we were only able to obtain information about WT BRCT 
protein interactions before and after treatment with OLP, which, however, still provide a 
valuable insight into the mechanism of OLP action. After applying the SAINT (Significance 
Analysis of INTeractome) algorithm to our data and setting a probability threshold of 0.8−1, we 
ended up with a list of 121 protein interactors (Figure 23B) (full list shown in Supplementary 
Table S4). Most of the proteins (108/121 = 89%) were found to interact with BRCT in both 
control and OLP-treated cells. However, 11 interactors were found to be specific only for OLP-
treated cells, several of them being involved in cellular proliferation, transcription or cellular 
signaling (Table 6). 
 
 
Figure 23. BRCA1 BRCT protein interactors in cells treated with DMSO or OLP. A) Coomassie staining of 
purified TAP-tagged BRCA1 BRCT constructs from DMSO- or OLP-treated HEK293FT cells. Arrows 
indicate the TAP-tagged bait protein. B) Venn diagram showing the number of proteins interacting with 
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WT BRCT after treatment with DMSO (control) or 16μM OLP. Only protein interactors which passed the 
SAINT cutoff of 0.8 and above were included. 
 
Table 6. BRCA1 BRCT interacting proteins specific for OLP-treated cells. (Source: www.genecards.org) 
Gene Gene name 
Protein 
(UniProtKB / 
Swiss-Prot) 
Mr 
(kDa) 
Fold change 
(OLP/DMSO) 
Main GO Biological processes 
ANKHD1 
Ankyrin repeat and 
KH domain-containing 
protein 1  
ANKH1 269 4 antiapoptotic effect; cell cycle 
AP2A1 
AP-2 complex subunit 
alpha-1  
AP2A1 108 4 intracellular transport; endocytosis 
ARID3B 
AT-rich interactive 
domain-containing 
protein 3B  
ARI3B 61 7 transcription regulation; cell cycle 
BORA 
Protein aurora 
borealis  
BORA 61 3 cell cycle 
CCDC102A 
Coiled-coil domain-
containing protein 
102A  
C102A 63 4 not defined 
INF2 Inverted formin-2  INF2 136 7 actin cytoskeleton organization 
ITPKB 
Inositol-trisphosphate 
3-kinase B  
IP3KB 102 5 cell surface receptor signaling 
MYO18A 
Unconventional 
myosin-XVIIIa  
MY18A 233 3 cell migration; function of Golgi 
NUMA1 
Nuclear mitotic 
apparatus protein 1  
NUMA1 238 3 
mitotic spindle orientation; chromatin 
remodeling; homologous 
recombination 
STRN Striatin  STRN 86 5 
positive regulation of estrogen 
receptor signaling 
STRN3 Striatin-3  STRN3 87 4 
neg. regulation of estrogen receptor 
signaling; regulation of transcription 
 
 
To get further insights into the functional roles of proteins interacting with the BRCA1 
BRCT domain, we performed an enrichment analysis of the set of 121 proteins by using 
Ingenuity Pathway Analysis (IPA), taking into account the value of fold change spectral counts. 
As expected, among the top canonical pathways related to this set of proteins was “Role of 
BRCA1 in DNA Damage Response”, which was found to be downregulated (as indicated by the 
negative z-score value of -1.6) and which indicates an alteration of this pathway by OLP 
treatment (Figure 24A). The interactors were also found to be significantly involved in several 
molecular and cellular functions, such as “DNA Replication, Recombination, and Repair” 
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(Figure 24B), and they were connected into a highly scored network within members of this 
function (score 61) (Figure 24C). 
 
110 
 
Figure 24. Functional analysis of the set of 121 BRCA1 BRCT-interacting proteins. A) Top five canonical 
pathways across the entire dataset. The significance was calculated with a Fisher’s exact test right tailed. 
The blue bar indicates predicted pathway inhibition after treatment with OLP. The pathways shown in 
grey color mean that no prediction can currently be made. The orange points connected with a thin line 
represent a ratio of genes from our dataset to all genes involved in this canonical pathway. B) Top 5 
molecular and cellular functions being related to the set of protein interactors. The orange line 
represents a significance threshold (P-value 0.05). C) IPA-based network of proteins involved in DNA 
Replication, Recombination, and Repair, Gene expression and Cell morphology functions with a score of 
61. 30 BRCA1 BRCT interactors were included in the 35 molecule output pathway. The legend specifies 
the molecule type, type of interaction, and up- (green) or down- (red) regulation of the protein binding 
after treatment with OLP. 
 
We were also able to detect a new BRCA1 phosphorylation site at position T1834 (located 
at the end of the C-terminal BRCT domain) in the OLP-treated cells. According to the 
PhosphoSitePlus database (www.phosphosite.org), there are 105 BRCA1 phosphorylation sites 
reported up to date and they are implicated in various cellular processes (Figure 25). However, 
the phosphorylation site at threonine 1834 has not been previously reported and could 
therefore represent an OLP-specific response. 
 
 
Figure 25. BRCA1 phosphorylation sites. A screenshot from the PhosphoSitePlus database showing the 
known phosphorylation sites of BRCA1 and their involvement in various cellular processes. 
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3.3 Gene expression profiling revealed downregulation of breast cancer-related 
genes as a response to OLP treatment 
 
After focusing our attention on the BRCA1 BRCT domain, we aimed to get a more global 
picture of the cellular response to PARP inhibitor OLP, and thus we searched for genes and 
miRNAs which are differentially expressed as a consequence of OLP treatment. We used 
DMSO-treated cells as controls and compared their gene and miRNA expression profiles to 
those of OLP-treated LCLs. 
We first checked the number of differentially expressed genes (FDR < 0.15 or logFC > 2 in 
absolute value) between DMSO- and OLP-treated WT cells and then we compared those 
numbers between WT cells, cells with missense mutations and cells carrying truncating 
mutations. Such comparison gave us an idea about inducement of an expression phenotype by 
OLP, taking into account the BRCA1 mutation status. 
Interestingly, when we used the most stringent threshold (FDR < 0.15) to identify OLP-
induced differential gene expression, we did not find any differentially expressed genes (DEg) 
in WT cells, however we detected 3842 DEg in mutated cells (missense and truncating 
together) (Figure 26A). After stratification according to the BRCA1 mutation type, only cells 
harboring truncating mutation had changed expression after treatment with OLP (2144 DEg). A 
closer look at the normalized pre-processed data revealed that most of these differentially 
expressed genes were of a low logaritmic fold change (Figure 26B), suggesting that the OLP-
induced changes were small, but very consistent.  
As we wanted to check the response of WT cells to OLP, i.e. the standard response of cells 
to OLP, we decided to use the second stringent threshold (logFC > |2|). We were able to 
identofy 312 genes which were differentially expressed after treatment of WTs with OLP 
(Figures 26B and 26C). IPA-based functional analysis of these genes revealed their involvement 
in numerous cancer-related molecular and cellular functions, including regulation of cell 
morphology and movement or cell death and survival (Figure 26D). Importantly, most of the 
DEg were related to the disease “Cancer” (p-value of 4.7x10-6), and the direction of their 
expression indicated a significant downregulation of “Cancer”-related genes upon treatment 
with OLP (as predicted from a negative z-score value of -2.019). 
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Figure 26. OLP-induced differential expression of genes in groups of LCLs and their implication in 
molecular functions. A) A diagram showing the numbers of OLP-induced differentially expressed genes 
with FDR < 0.15 in WT, missense (MIS), truncating (TRUN), and mutated (MUT = MIS + TRUN) LCLs. B) A 
graph displaying the numbers of differentially expressed genes (logFC > |2|) after treatment with OLP in 
WT, MIS, TRUN, and MUT LCLs. C) Venn diagram illustrating the number of genes being differentially 
expressed after treatment with OLP (logFC > |2|) in WT cells, or LCLs harboring MIS or TRUN mutation. 
For each comparison, the overlap of genes is shown. The numbers highlighted in blue are up- or down-
regulated genes in WT cells. The underlined number represents OLP-induced DEg specific only for WT 
and TRUN, but not for missense. D) Top 5 molecular and cellular functions being associated with genes 
differentially expressed after OLP treatment of WT cells. The orange line represents a significance 
threshold (P-value 0.05). 
 
 
Using the MALACARDS database (http://www.malacards.org/) of genes involved in human 
diseases, we searched whether any of the 289 reported breast cancer-associated genes were 
differentially expressed in our WT samples after treatment with OLP. Interestingly, 4 
commonly upregulated breast cancer genes (ERBB2, FOS, HSPB2, AGR3) were found to be 
downregulated by OLP, indicating that this treatment could have additional positive effects 
than just a simple synthetic lethality. 
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3.4 miRNA expression is changed by OLP treatment and regulates expression of 
breast cancer-related genes ERBB2 and FOS 
 
The final high throughput method we used in order to better understand the response of 
cells to OLP was miRNA expression profiling and its integration with gene expression. As in the 
case of gene expression, we first checked the numbers of differentially expressed miRNA 
(DEm). Interestingly, the miRNome was strongly affected by OLP treatment in all groups of 
cells (Figures 27A and 27B), however the absence of any DEm when applying the significance 
threshold of logFC > |2| suggests that the expression of these miRNAs is consistent between 
cell lines but does not change dramatically after treatment with OLP. 
As obvious from the Figure 27B, most of the OLP-induced DEm were common for all 
groups of LCLs (154 miRNAs). To check the standard changes in miRNA expression induced by 
PARP inhibitor OLP, we focused on WT cells and with the help of IPA we performed the 
integration study between the 187 DEm and the 321 DEg. After several filtering steps 
(selection of miRNAs recognized by IPA, miRNAs with experimentally validated targets, miRNA-
mRNA pairs showing anti-correlated expression pattern), we selected 7 DEm targeting 9 DEg 
(Table 7). Interestingly, the list of miRNA targeted genes included FOS and ERBB2, the breast 
cancer related genes, whose expression was downregulated in WT cells by OLP treatment. The 
OLP-induced upregulation of miR-222-3p and miR-548ap-5p and subsequent downregulation 
of FOS or ERBB2 gene expression, respectively, indicate the complexity of action of PARP 
inhibitor OLP. 
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Taking into account the apparent importance of this cascade in response of cells to OLP, 
we checked the expression of these two miRNAs and their two gene targets in LCLs harboring 
missense or truncating mutation in BRCA1 gene. Surprisingly, both miR-222-3p and miR-548ap-
5p were found to be significantly upregulated in both WTs and cells with truncating mutation, 
however, they were significantly downregulated in cells carrying missense mutation (Table 8). 
In addition, FOS expression was significantly downregulated in WTs and cells with truncating 
mutation (Table 8; Figure 26C – underlined number), but not in cells harboring missense 
mutation. These results indicate that OLP-induced regulation of FOS expression could be at 
least partially responsible for the observed differences in sensitivity of cells to PARP inhibitor 
OLP (Figure 20A), and confirm distinct effects of the various types of BRCA1 mutation. 
Importantly, these results also indicate that breast cancer patients carrying BRCA1 mutation 
are likely to show different toxicity to PARP inhibitor OLP, depending on the mutation type, 
and possibly also variability in the response to these agents. 
 
 
Figure 27. OLP-induced differential expression of miRNAs in groups of LCLs depending on their BRCA1 
mutation status. A) A diagram showing number of OLP-induced differentially expressed miRNA with 
FDR < 0.05 in WT, missense (MIS), truncating (TRUN), and mutated (MUT = MIS + TRUN) LCLs. B) Venn 
diagram illustrating the number of miRNAs being differentially expressed after treatment with OLP (FDR 
< 0.05) in WT cells, or LCLs harboring MIS or TRUN mutation. For each comparison, the overlap of 
miRNAs is shown. The numbers highlighted in blue are up- or down-regulated miRNAs in WT cells. 
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Table 8. OLP-induced differential expression of miR-222-3p and miR-548ap-5p and their target genes 
FOS and ERBB2, respectively, in panel of LCLs. FDR < 0.15 and logFC > |2| were considered as 
significance thresholds for miRNAs and genes, respectively. 
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1 Impaired DNA repair capacity and gene expression indicate 
haploinsufficiency in healthy heterozygous BRCA1 mutation carriers 
BRCA1 plays a critical role in various cellular processes, including DNA repair, cell cycle 
regulation, transcriptional activation, and ubiquitin ligation (Zhang and Powell 2005). Carrying 
an inherited mutation in this gene significantly increases individual´s lifetime risk to develop 
breast, ovarian and other cancers (Antoniou, Pharoah et al. 2003; Chen, Iversen et al. 2006; 
Milne, Osorio et al. 2008). BRCA1 is considered as a tumor suppressor gene, i.e. both alleles of 
the gene have to be affected to impair its function and a single “hit” is not sufficient to enable 
cancer development (Knudson 1971). However, it has been suggested in several studies that a 
mutation in one allele of BRCA1 could already affect some of its functions and such 
haploinsufficiency might accelerate the loss of the second allele and lead to carcinogenesis 
(Gayther, Warren et al. 1995; Thompson, Easton et al. 2002; Waddell, Ten Haaf et al. 2008; 
Drost and Jonkers 2014). Moreover, taking into account the variability in disease manifestation 
among mutation carriers it is possible that different BRCA1 mutations have diverse phenotypic 
and haploinsufficiency effects and that both type and location of mutation may influence 
cancer initiation and response to treatment. 
In the first part of the thesis, we aimed to gain a better understanding of the molecular 
and biological mechanisms which predispose BRCA1 mutation carriers to hereditary breast 
cancer by investigating the mechanism of haploinsufficiency in LCLs carrying different types of 
germline truncating and missense mutations. Using this cellular model, we analyzed BRCA1 
expression, DNA repair capacity, and gene and miRNA expression profiles. 
 
1.1 Cells derived from BRCA1 mutation carriers show variable BRCA1 expression, 
depending on the mutation type 
First, we aimed to determine whether cells derived from carriers of various types of 
BRCA1 mutations (missense versus truncating) show altered expression at mRNA and protein 
levels. As expected, we found significantly decreased BRCA1 mRNA expression in cells 
harboring truncating mutation, indicating that the truncated transcripts were most probably 
subjected to a degradation by the nonsense-mediated mRNA decay (NMD) pathway (Conti and 
Izaurralde 2005). Our findings are also in agreement with the study published by Perrin-Vidoz 
et al., demonstrating that most of the BRCA1 transcripts containing a premature termination 
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codon (PTC) are degraded by NMD which leads to up to 5-fold reduction in mRNA abundance 
(Perrin-Vidoz, Sinilnikova et al. 2002). Consistently with the probable degradation of PTC-
containing transcripts, we were unable to detect any truncated protein in our optimized 
Western blotting experiments. It has been proven that some mutations fail to trigger NMD 
because of translation re-initiation, which is the case of the BRCA1 mutation c.68_69delAG 
(Buisson, Anczukow et al. 2006). However, we didn’t detect such truncated protein suggesting 
that it was probably degraded after its synthesis. These findings are in agreement with 
previous reports (Buisson, Anczukow et al. 2006; Anczukow, Ware et al. 2008) and indicate 
that endogenously expressed truncated BRCA1 are highly unstable and is possible to detect 
them by Western blotting only when overexpressed. 
On the contrary to truncating mutations, the BRCA1 mRNA level in cells with 
heterozygous missense mutation was comparable to WT LCLs, indicating that the mutated 
mRNA transcripts are stable, which is in agreement with previously published results (Lovelock, 
Healey et al. 2006; Bouwman, van der Gulden et al. 2013). In addition, the average level of the 
total full-size BRCA1 protein was also similar to the level found in controls. Such finding was 
surprising because previous studies indicated that particularly these two mutants 
(p.Ala1708Glu and p.Gly1706Glu) have a severe folding defect which leads to destabilization of 
the protein structure (Lovelock, Healey et al. 2006; Lee, Green et al. 2010; Rowling, Cook et al. 
2010). Further analysis of our results revealed that two of the three LCLs harboring the 
p.Ala1708Glu mutation showed lower level of total BRCA1 protein than those carrying 
p.Gly1706Glu. The discrepancy in the stability of these two BRCA1 variants could be explained 
by a previously reported partial skipping of mutated exon 18 in cells with p.Ala1708Glu 
mutation which might give rise to even less stable protein (Millevoi, Bernat et al. 2010). 
Importantly, the presence of non-degraded mutated protein brings the possibility of a 
dominant-negative effect of the altered product on WT protein functions. It has been 
described already more than 10 years ago by Fan and colleagues that non-degraded truncated 
or mutated full-length BRCA1 proteins can abrogate some functions of the remaining WT 
BRCA1 allele (Fan, Yuan et al. 2001). Consistently with these results, it has also been found that 
the presence of BRCA1-∆(1808−5556) truncated protein in mouse epithelial ovarian cancer cell 
line, which contains two endogenous BRCA1 WT alleles, leads to an increase of tumorigenicity 
in vivo and chemosensitivity (Sylvain, Lafarge et al. 2002). A more recent paper from Coene 
and colleagues shows the competition of the recombinant C-terminal BRCA1 fragment for 
binding to F-actin (Coene, Gadelha et al. 2011), further supporting the possibility of a 
dominant-negative function of BRCA1 mutated protein. Results from these studies together 
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with our findings suggest that the dominant-negative phenomenon could play a considerable 
role in hereditary breast and ovarian cancers, especially in carriers of BRCA1 missense 
mutations which maintain the mutated proteins in cells. 
 
1.2 Heterozygous mutations in BRCA1 gene lead to haploinsufficiency in the 
repair of spontaneously occurring DNA damage 
The observed differences in BRCA1 mRNA and protein expression between LCLs also 
encouraged speculations about haploinsufficiency and manifestation of distinct phenotypes 
depending on the BRCA1 status. Taking into account the role of BRCA1 in several DNA repair 
pathways, we aimed to evaluate the level of spontaneously occurring or IR-induced DNA 
damage (measured by detection of gamma-H2AX nuclear signal) and the efficiency of DSB 
repair (evaluated by counting number of RAD51 nuclear foci) in different LCLs. We were able 
to demonstrate that, at the basal conditions, LCLs established from mutation carriers showed 
increased level of DNA damage, measured by the intensity of gamma-H2AX nuclear signal. 
Interestingly, the same cells also showed increased proportion of hyper-phosphorylated 
BRCA1. As various sets of Ser residues are being phosphorylated throughout cell cycle and in 
response to DNA damage (Thomas, Smith et al. 1997; Okada and Ouchi 2003), and we didn’t 
find any significant differences in the cellular growth rate between control and mutated LCLs, 
it is likely that the increased ratio of hyper-P BRCA1 in mutated cells was a consequence of a 
higher requirement of the active (phosphorylated) protein due to the elevated level of DNA 
damage. 
It´s worth to note that cells harboring BRCA1 truncating mutation showed the highest 
level of DNA damage at basal conditions and also displayed the highest ratio of hyper-P/hypo-
P BRCA1. These results highlight the differences between distinct types of BRCA1 mutations 
and suggest that increased DNA damage (in particular dangerous DSBs) might be implicated in 
the initial steps of breast cancer development in carriers of truncating mutations. 
Interestingly, we also observed a significantly lower amount of RAD51 foci in non-
irradiated mutated LCLs when compared to control cells grown under basal conditions, 
indicating haploinsufficiency of mutated cells in DNA repair. Although we did not find such 
altered RAD51 foci formation in irradiated cells, more RAD51 foci would be expected to be 
formed in mutated cells taking into account the elevated level of DNA damage caused by 
irradiation with respect to controls. Thus, it makes us to interpret the equal level of RAD51 foci 
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as an actual defect of DNA repair in mutated cells. Moreover, RAD51 protein levels in the 
western blot were similar among LCLs suggesting that BRCA1 haploinsufficiency results in 
impairment of RAD51 foci formation but not of the maintenance of normal protein levels, 
being in line with a prior study (Bhattacharyya, Ear et al. 2000). 
These results indicate that the presence of one mutated allele in the BRCA1 gene may 
already lead to DNA repair defects and that these cells are therefore haploinsufficient for 
repair of such damage which could be implicated in initial steps of neoplastic transformation 
and increased susceptibility to cancer. Our observation that heterozygous mutations in BRCA1 
gene could lead to haploinsufficiency in the repair of spontaneously occurring DNA damage are 
also in line with other previously published studies. For example, Konishi et al. used MCF10A 
non-tumorigenic human breast epithelial cells MCF10A and introduced a common BRCA1 
c.68_69delAG mutation into one BRCA1 allele and described impaired HR-mediated DSB repair 
(Konishi, Mohseni et al. 2011). Our results are also in agreement with the observation of a 
spontaneous hyper-recombination phenotype and reduced efficiency of HR repair of DSBs in 
MCF7 cells carrying only a single BRCA1 allele (Cousineau and Belmaaza 2007). However, most 
of other studies found impaired DNA repair only after irradiation of BRCA1 heterozygous cells. 
The elevated level of spontaneously occurring DSBs together with impairment of their 
repair could increase the toxicity related to a DNA-damaging treatment in BRCA1 mutation 
carriers. In this regard, it has been suggested that BRCA1/2 mutation carriers could be at 
higher risk to develop specific side effects related to chemotherapy (Huszno, Budryk et al. 
2013). Therefore, a further investigation on therapy-induced toxicity in carriers of various 
BRCA1 mutations would be recommended in the future. 
 
1.3 Gene expression profiles vary depending on the BRCA1 mutation status, 
indicating differences in haploinsufficiency and phenotypic effects 
In order to identify genes which would discriminate the LCLs according to their BRCA1 
mutation status we performed a gene and miRNA expression analysis in non-treated cells. 
Unsupervised hierarchical cluster of expression differences between control cells and LCLs 
from BRCA1 mutation carriers suggested that monoallelic BRCA1 mutations do not lead to 
dramatic changes in gene expression profile (Fig. 4). These results are consistent with a study 
published by Kote-Jarai and colleagues, where they analyzed expression profiles of normal skin 
fibroblasts isolated from carriers of BRCA1 or BRCA2 mutation (Kote-Jarai, Matthews et al. 
123 
 
2006). In this study they were able to predict BRCA1/2 carrier genotypes only after induction 
of DNA damage after irradiation, but not under basal conditions. Similarly, Salmon et al. 
reported the inability to distinguish non-carriers of BRCA1 mutation from mutation carriers 
based on expression profiling of non-treated LCLs (Salmon, Salmon-Divon et al. 2013). 
However, we noticed that cells harboring missense mutation tended to cluster away from 
the rest. Consistently with this finding, we observed the highest number of differentially 
expressed genes when comparing LCLs with missense mutation and controls. The fact that we 
found less differentially expressed genes when analyzing WT vs all mutated LCLs than when 
comparing WT cells with any of the mutation type alone suggests differences in effects of the 
two types of mutations. Similarly to our results, it has also been shown by Waddell et al. that 
missense pathogenic mutations in BRCA1 show distinct expression profile which is more 
similar to BRCAX individuals than BRCA1/2 samples (Waddell, Ten Haaf et al. 2008). Taking into 
account the comparable BRCA1 protein level between WTs and cells with missense mutation 
and their distinct expression profiles, it is possible that the presence of non-degraded mutated 
protein could either have a dominant negative effect on the WT protein functions or could 
lead to occurrence of novel protein interactions and activation of alternative pathways. 
Interestingly, there was an overrepresentation of immune response-related genes (IFNG, 
IRF5, ICOS, ITGB5) that were downregulated in LCLs harboring missense mutation, suggesting 
that this pathway might be altered specifically in carriers of these particular mutations (Table 
2). Moreover, looking at the Catalogue of somatic mutations in cancer (COSMIC), we observed 
that IFNG, IRF5, ICOS have been previously found to be mutated in ductal breast carcinoma 
and three out of the four downregulated genes (IRF5, ICOS, ITGB5) were described to be 
mutated in serous ovarian carcinoma. Importantly, Feilotter et al. have recently published a 
study showing alteration of gene expression due to BRCA1 haploinsufficiency and, consistently 
with our results, they also detected alterations in the interferon-regulated transcriptional 
pathway in LCLs harboring monoallelic BRCA1 mutations (Feilotter, Michel et al. 2014). It has 
also been shown that the tumor suppressor IRF5 is down regulated in patients with ductal 
carcinoma in situ and invasive ductal carcinoma and that loss of this gene correlates with 
increased invasiveness (Bi, Hameed et al. 2011). In addition, the involvement of the 
differentially expressed genes in cancer-relevant functions (such as cell death, cellular 
movement and proliferation) indicate that these molecular functions and the immune 
response pathway may be deregulated under conditions of BRCA1 haploinsufficiency and that 
such deregulation could contribute to a neoplastic transformation. 
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Another interesting gene than we found to be downregulated in carriers of BRCA1 
missense mutations was PPARG (peroxisome proliferator-activator receptor gamma) that has 
been previously shown to be connected to breast carcinogenesis. This nuclear receptor acts as 
a tumor suppressor and the loss of its expression has been shown to contribute to creation of 
protumorigenic environment in breast tissue (Skelhorne-Gross, Reid et al. 2012; Apostoli, 
Skelhorne-Gross et al. 2014). Therefore, the downregulation of this tumor suppressor could, 
together with impaired functions of BRCA1, could contribute to the increased susceptibility of 
carriers of specific BRCA1 missense mutations (p.Ala1708Glu, p.Gly1706Glu) to breast cancer. 
Our results from gene expression profiling suggest that mutation in one of the two alleles 
of the BRCA1 gene may lead to insufficient maintenance of gene expression. Moreover, we 
have found that cells harboring missense mutations show more altered pathways than those 
with truncating mutations when compared with controls, which suggest that different 
mutations could give rise to differences in haploinsufficiency and phenotypic effects. These 
findings could contribute to a better understanding of the initial steps of hereditary breast 
cancer and could also have implications for the surveillance and treatment of cancer patients. 
 
2 Cells carrying germline missense mutation in BRCA1 show 
increased sensitivity to the PARP inhibitor OLP 
Various PARP inhibitors are currently being tested in numerous preclinical or clinical trials 
in patients with sporadic/hereditary breast, ovarian and other cancers. The promissing results 
from phase II studies in BRCA1/2-mutated breast and ovarian cancers allowed to proceed to a 
more advanced phase III (Burgess and Puhalla 2014; Liu, Konstantinopoulos et al. 2014). 
Despite the success, a substantial fraction of patients displayed resistance to the treatment 
(Fong, Boss et al. 2009), which could be at least partially explained by secondary mutations in 
BRCA1/2 genes, remaining a basal activity of mutated BRCA1 protein, upregulation of P-
glycoprotein efflux pumps, loos of 53BP1, or overexpression of PARP1 (Rottenberg, Jaspers et 
al. 2008; Drost, Bouwman et al. 2011; Barber, Sandhu et al. 2013; Jaspers, Kersbergen et al. 
2013; Gilabert, Launay et al. 2014). 
Taking into consideration the phenotypic variability between BRCA1 mutation carriers, the 
second objective of this thesis was to investigate whether and how BRCA1 mutation type 
influences the sensitivity of cells to PARP inhibitors. In addition, the factors which could 
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influence the response of cells to PARP inhibitors olaparib (OLP) and veliparib (VLP), such as 
PARP1 expression and enzymatic activity or cellular growth rate, were examined. 
 
2.1 Carriers of heterozygous truncating mutation in BRCA1 show reduced 
expression of PARP1 
First, we wanted to validate the previously described synthetic lethal interaction between 
BRCA1 and PARP1 (Bryant, Schultz et al. 2005; Farmer, McCabe et al. 2005) by testing OLP and 
VLP in BRCA1-proficient and -deficient breast cancer cells. As expected, BRCA1 knockdown in 
BRCA1-proficient breast cancer cell line MDA-MB-231 led to a decrease in cellular viability 
after treatment with these PARP inhibitors. In addition to our proliferation experiment, we 
also observed a reduced ability to form colonies in PARP inhibitor-treated BRCA1-depleted 
cells, which further confirms the synthetic lethal interaction between BRCA1 and PARP1. The 
observed variability in the ability to create colonies which was detected between sh1 and sh5 
was not related to their BRCA1-knockdown efficiency, as both of them silenced the gene in a 
similar level. Instead, it was probably related to its random integration in the MDA-MB-231’s 
genome, which could have led to an occurrence of additional mutation, and thus to a different 
response to the treatment. 
We then examined several factors which could potentially influence the response of cells 
to PARP inhibitors. Unexpectedly, we found that PARP1 expression was downregulated in cells 
harboring truncating mutation in BRCA1. As these cells also express lower levels of BRCA1, it is 
possible that BRCA1 helps to maintain normal PARP1 expression. Such connection between 
BRCA1 and base excision repair pathway members is not new because it has been previously 
reported that BRCA1 stimulates the base excision repair pathway by increasing the activity of 
OGG1, NTH1, and REF1/APE1 (Saha, Rih et al. 2010). The role of BRCA1 deficiency in this 
phenotype was further confirmed by a decreased PARP1 expression in MDA-MB-231-sh1 cells, 
even though only a weak PARP1 expression downregulation was observed in these cells. Such 
variation could be explained by differences between these two cellular models or by just a 
partial control of PARP1 expression by BRCA1.  
As various studies indicate that PARP1 expression correlates with its enzymatic activity 
only partially (Zaremba, Ketzer et al. 2009; Zaremba, Thomas et al. 2011), we decided to 
measure the activity of this enzyme by two methods. Neither detection of PAR polymers by 
Western blot (a less accurate measurement) nor in vitro PARP activity assay revealed any 
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significant differences between groups of LCLs, confirming the independency of PARP activity 
on the level of protein expression. Nevertheless, an elevated PARP activity in cells harboring 
missense mutation in comparison to cells with truncating mutation, found in both assays, 
indicates differences between these mutation types and could modulate their response to the 
drug. 
 
2.2 The type of BRCA1 germline mutation influences the sensitivity of cells to OLP 
We then evaluated the differences in the sensitivity to OLP according to the BRCA1 
mutation type. Consistently with the Knudson’s model of “two-hit” hypothesis for tumor 
suppressors, treatment with OLP led to a comparable sensitivity of cells harboring 
heterozygous truncating mutations as in WT cells. Taking into account that we detected lower 
levels of BRCA1 and PARP1 in cells with truncating mutations, our results indicate that the 
expression levels of these two proteins are not associated with the response of these cells to 
OLP. However, it was interesting to find out that cells with heterozygous missense mutation in 
BRCA1 were significantly more sensitive to the treatment then both WTs and cells with 
truncating mutation. These findings again highlight the different behavior of missense and 
truncating mutants and indicate it might be beneficial to consider them separately in the 
clinics. 
By analyzing the factors which could influence the response of cells to OLP, we found that 
the higher is the PARP enzymatic activity, the lower is the viability of cells after the treatment. 
Such negative correlation indicates that the sensitivity to OLP is, at least partially, dependent 
on the ability of PARP to play its enzymatic role. Previous research by Gottipati et al. shows 
that hyperactivation of PARP1 is associated with an increased sensitivity of cells to PARP 
inhibitors, and they relate the increased sensitivity to these agents to a homologous 
recombination-defective phenotype (Gottipati, Vischioni et al. 2010). Our results from 
immunofluorescence experiment indicate that cells harboring either of the BRCA1 mutation 
types show alteration in DNA repair, as shown by a significantly decreased level or RAD51 foci. 
However, our experimental desing allows only indirect evaluation of homologous 
recombination efficiency, which brings the possibility that a more stringent assay (e.g. the 
Traffic Light Reporter System described by (Certo, Ryu et al. 2011) could reveal additional 
differences between missense and truncating mutations. As expected, the cellular growth rate 
positively correlated with the viability of OLP-treated cells, which is in line with other studies 
showing that rapidly dividing cells are more sensitive to DNA damaging agents (Stark, Zhang et 
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al. 2010). However, the significant differences in response of mutated cells to OLP or VLP were 
maintained after incorporating the growth rate as a covariate, indicating that the difference in 
sensitivity to the agent is independent on the growth rate. 
Taking into account the expected presence of mutated protein in cells carrying missense 
mutation and the absence of truncated protein in cells with truncating mutation, there is a 
possibility that the missense mutants act in a dominant negative manner on the WT protein 
function. Considering our results, we propose a model which involves a dominant negative 
effect of the BRCA1 BRCT missense mutant and a previously described two-phase BRCA1 
recruitment to the DNA DSBs (Baer 2013; Li and Yu 2013). Based on the research carried on by 
Li et al., WT BRCA1 heterodimerizes with BARD1 through its RING domain and is recruited into 
DSBs by interaction of BARD1 with PAR polymers within an minute post damage (early 
recruitment) (Figure 28). On the other hand, during the late recruitment, BRCA1 is directed 
into damaged chromatin within minutes after damage. The later phase requires functional 
BRCA1 BRCT domains and is dependent on a direct interaction with p-Abraxas, a member of a 
BRCA1-A complex subunit. 
OLP treatment inhibits the early recruitment of BRCA1 into DSBs by inhibition of PAR 
polymeration, which makes the cells more dependent on the late recruitment phase. Cells 
harboring heterozygous truncating mutation in BRCA1 gene usually lack the mutated protein 
due to the degradation of a mutated transcript by NMD mechanism. But the remaining WT 
protein can function in the DSB repair through late recruitment phase. On the contrary, cells 
carrying heterozygous missense mutation in BRCA1 contain both the functional (WT) and 
defective (mutant) proteins which could compete to undergo the late recruitment path to 
repair DNA DSBs. In addition, the slight elevation of PARP activity in these cells makes them 
even more dependent on the late phase after treatment with OLP. We therefore hypothesize 
that the competition of mutated and WT protein could lead to and alteration the DNA repair 
process and decreased viability of cells carrying BRCA1 missense mutation. 
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Figure 28. Two-phase recruitment of BRCA1 to distinct subcompartments of a DSB. During the early 
recruitment hase, BRCA1 interacts with BARD1 through their RING domain and a recruitment of the 
heterodimer into DSB is mediated by BARD1 BRCT recognition of PAR. On the other hand, the late phase 
is dependent on BRCA1 BRCT domains and their interaction with phosphorylated Abraxas. Adapted from 
Baer et al., based on the results from Li et al.  
 
Importantly, the OLP concentration range, which was used in our experiments, was 
comparable to the peak plasma levels found in patients treated with these agents in clinical 
trials (Fong, Boss et al. 2009). On the other hand, the VLP concentrations used in our 
experiments were few fold higher than the maximal plasma levels in treated patient or animals 
(Donawho, Luo et al. 2007; Kummar, Kinders et al. 2009). Higher VLP dosage was also used in 
our breast cancer cellular model with silenced BRCA1 in order to achieve synthetic lethality 
between BRCA1 and PARP1, and such high concentrations were also necessary in other in vitro 
studies (Horton, Jenkins et al. 2009; Stordal, Timms et al. 2013). Such difference between PARP 
inhibitors could be related to a lower potency of VLP to trap PARP1 at the DNA damage site 
(Murai, Huang et al. 2012), an alternative mechanism of function of PARP inhibitors, and is a 
reason behind choosing OLP for exploring the mechanism of action of PARP inhibitors in 
mutation carriers. 
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3 OLP changes BRCA1 BRCT protein interactors and leads to 
downregulation of breast cancer-related genes ERBB2 and FOS 
In the last part of the thesis, we aimed to explore the mechanism of increased sensitivity 
of cells carrying missense mutation to PARP inhibitor OLP. We used transcriptional assay to 
assess how BRCA1 missense variants and OLP treatment influence the ability of cells to 
activate transcription of target genes. In addition, utilizing the mass spectrometry technique 
allowed us to determine the OLP-specific BRCT-protein interactors. Finally, we explored which 
genes or miRNAs are involved in the response of LCLs to this PARP inhibitor and performed 
integration of the high-throughput data. 
 
3.1 Transcriptional activation function of the BRCA1 BRCT domain does not seem 
to be involved in the response of cells to OLP 
There are several structural and functional assays, including protease sensitivity, peptide 
binding activity and specificity, and transcriptional activity assays, which have been developed 
to test specific functions of BRCA1 and to determine the effect of BRCA1 variants (Lee, Green 
et al. 2010). The missense mutations represented in our panel of LCLs are located specifically 
in the BRCA1 BRCT domain, which is known to be involved in the maintenance of genomic 
stability and transcriptional activation of target genes (Roy, Chun et al. 2011). Therefore, we 
used a well described transcriptional activation assay to check how the missense variants and 
OLP treatment influence this BRCT-related function. As expected, WT protein strongly induced 
transcription of the target gene, whereas both missense variants disrupted the transcriptional 
activation function of BRCA1. These findings are in agreement with previous studies and 
indicate the pathogenicity of these missense mutations (Phelan, Dapic et al. 2005; Carvalho, 
Pino et al. 2009; Lee, Green et al. 2010). In order to mimic the heterozygous status present in 
mutated LCLs, we also overexpressed both WT and A1708E missense variant which allowed us 
to explore a potential dominant negative effect of the mutated protein. However, we observed 
that a simultaneous expression of both WT and mutant variant did not affect the phenotype 
and the transcriptional activation was comparable to the response of WT alone, suggesting 
that the variant does not influence the WT transcriptional activation function in a dominant 
negative manner. Interestingly, OLP treatment led to a slight decrease of the transcriptional 
activation, however only less than 50% of the WT activity is generally considered as deleterious 
(Carvalho, Pino et al. 2009). Hence this function of the BRCA1 BRCT domain seems not to be 
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dramatically affected by OLP treatment and our results indicate that the increased sensitivity 
of cells carrying heterozygous missense mutation to OLP is not related to an alteration of the 
BRCA1 transcriptional activation function. 
 
3.2 OLP downregulates the interaction of BRCA1-A complex with BRCA1 and 
induces phosphorylation of threonine residue at position 1834 
The ability to activate transcription of target genes is not the only function mediated by 
the BRCT domain of BRCA1. The number of BRCT protein interactors allows BRCA1 to play a 
role also in such complex cellular processes like cell cycle checkpoint regulation and 
maintenance of genomic stability (Roy, Chun et al. 2011). Thus, in order to further puzzle out 
whether and how OLP treatment affects functions mediated by the BRCA1 BRCT domain, we 
looked at the BRCA1 BRCT protein interactors in OLP-treated cells. From the 121 BRCT 
interactors, identified using a proteomics approach, most of them were found in both control 
and OLP-treated cells, indicating that the treatment did not lead to dramatic changes of 
protein complexes. The 11 identified OLP treatment-specific BRCA1 BRCT interactors were 
found to be involved in various biological processes, such as cell cycle and transcription 
regulation (www.genecards.org). The most interesting protein from the selection was NUMA1 
because it has been previously described as an acceptor of PAR polymers from tankyrase 1 
(PARP-5a). Such PARylation of NUMA1 is required for a proper assembly of mitotic spindle 
pole, chromatin remodeling, and RAD51-dependent homologous recombination repair (Chang, 
Dynek et al. 2005; Chang, Coughlin et al. 2009; Vidi, Liu et al. 2014). Moreover, it has also been 
recently suggested that NUMA1 forms a complex with BRCA1, PARP-5a, and ATM, and that 
creation of this protein complex is required for the PARylation of NUMA1 and its proper 
function in mitosis (Palazzo, Della Monica et al. 2014). However, as PARP inhibitor OLP does 
not inhibit enzymatic activity of PARP-5a (Wahlberg, Karlberg et al. 2012), it is likely that OLP-
treatment and the subsequent increased binding of NUMA1 to BRCA1 does not affect function 
of NUMA1. 
Unexpectedly, OLP treatment induced phosphorylation of BRCA1 on the threonine 
residue at position 1834 which is located at the very end of the C-terminal BRCT domain. 
Phosphorylation of more than 100 distinct sites have been identified in BRCA1 up to date 
(www.phosphosite.org), however their involvement in various cellular processes is elucidated 
only for some of them. For example, it has been known already for a long time that ATM-
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dependent phosphorylation of S1423 and S1524 is critical for BRCA1-mediated DNA damage 
response (Cortez, Wang et al. 1999) and activation of UV-induced apoptosis (Martin and Ouchi 
2005). On the other hand, a promotion of error-free HR and suppression of the error-prone 
NHEJ repair pathways is independent on the phosphorylation on serines 1423 and 1524, and is 
related to a Chk2-mediated phosphorylation at S998 (Zhang, Willers et al. 2004). As the OLP-
induced phosphorylation of T1834 has not been previously described, we can only hypothesize 
that it might serve as an activator of downstream pathways related to a response to this 
treatment. 
In order to shed light on the molecular processes regulated by the set of BRCA1 BRCT 
interactors and to determine how OLP could influence these processes, we performed an 
enrichment analysis with IPA. The investigation revealed that BRCA1 interacts with proteins 
involved in canonical pathways such as DNA damage response, hereditary breast cancer and 
oestrogen signaling, or assembly of RNA polymerase II Complex. Such results are in line with 
previously known roles of BRCA1 BRCT in the maintenance of genome integrity and regulation 
of cell cycle checkpoint and gene expression (Roy, Chun et al. 2011). Consistently with these 
results, the BRCT interactors also created a network of interconnected proteins which were 
mainly involved in DNA replication, recombination, repair, gene expression functions. 
Interestingly, the canonical pathway “Role of BRCA1 in DNA Damage Response” seemed 
to be downregulated upon OLP treatment. In particular, most of the members of the BRCA1-A 
complex (RAP80, BRCC3, Abraxas), showed decreased binding to BRCA1 BRCT in response to 
OLP treatment. As this complex plays a crucial role in DNA damage response by recognition of 
ubiquitinated H2AX and recruiting BRCA1 into the DNA damage site (Wang, Matsuoka et al. 
2007; Wang, Hurov et al. 2009), our results indicate that OLP treatment might partially inhibit 
this BRCA1-mediated function. Coming back to our model of dominant-negative effect of 
missense variants, it seems that OLP treatment does not only inhibit the PAR-dependent early 
phase but partially also the BRCA1-A complex-dependent late phase of BRCA1 recruitment into 
DSBs in normal cells. This could make the cells dependent on the remaining function of the late 
BRCA1 recruitment phase in case of DSBs occurrence. The potential competition of the WT and 
defective BRCA1 protein in carriers of BRCA1 missense mutation could thus lead to intolerable 
effects and consequently to a decreased viability of OLP- treated mutant cells. 
The inability to perform an identical analysis of the protein interactors of mutated BRCA1 
only allowed us to speculate that cells carrying missense mutation in this domain could display 
a different set of protein interactors. The mutation-mediated change of interacting partners or 
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their abundance could then alter the response of mutated cells to OLP treatment and might 
also disrupt their ability to phosphorylate the OLP-specific T1834 site. Clearly, further 
methodological optimalization will be necessary to express the mutated BRCA1 BRCT in a 
sufficient level and to be able to address our speculations. 
 
3.3 PARP inhibitor OLP changes gene and miRNA expression profiles and 
downregulates expression of breast cancer-related genes ERBB2 and FOS 
The transcriptional activation assay and mass spectrometry approach gave us an idea of 
which BRCA1-BRCT-related functions are changed in response to PARP inhibition by OLP. In 
order to get more complex understanding of the cellular response to OLP and the effect of 
BRCA1 mutation type in sensitivity of cells to this agent we studied genes and miRNA 
expression in our panel of treated LCLs. 
It was surprising that when we used the most stringent threshold of significance 
(FDR < 0.15) we found more than two thousand DEg between DMSO- and OLP-treated LCLs 
harboring truncating mutation in BRCA1, but no genes showed differential expression in WTs 
or cells with missense mutation. Looking at the data for each particular truncating cell line 
revealed that OLP induced only small but very consistent changes in gene expression. On the 
contrary, the OLP-mediated changes of gene expression were much higher and not so 
consistent among WT cells, as indicated by the high number of genes showing more than 2-
fold logarithmic change.  The inability to detect any DEg in WT or missense LCLs when applying 
FDR < 0.15 was probably related to a lower number of cell lines in these two groups. In 
addition, a clear outlying pattern of one WT DMSO-treated cell line (11S66-L) probably 
contributed to an increased heterogeneity between LCLs and did not allow any gene to reach 
the stringent significance threshold. 
By investigating the OLP-induced DEg in WT cells (using the less stringent threshold, 
logFC > |2|) we found 312 DEg and got better idea about the standard response of cells to this 
agent. The functional analysis of these 312 genes with IPA revealed a significant 
downregulation of cancer-related genes in OLP-treated cells, which could indicate that the 
global effect of this agent is not damaging in non-mutated cells. Interestingly, four well 
described breast cancer-related genes (ERBB2, FOS, HSPB2, AGR3) were found to be 
significantly downregulated by the treatment. The amplification and/or overexpression of 
ERBB2 have been related to breast, ovarian, and other cancers (Hynes and Lane 2005). Breast 
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cancer patients expressing high levels of this protein are nowadays treated with Herceptin, a 
humanized monoclonal antibody against the extracellular domain of ERBB2, which can delay 
mortality from 9 months to 3 years (Slamon, Leyland-Jones et al. 2001). The second 
downregulated gene in response to OLP was FOS which encodes a leucin zipper protein and 
forms part of the transcription factor complex AP-1 (Jochum, Passegue et al. 2001). There are 
many evidences of the connection of FOS with breast cancer, e.g. it has been described to 
support growth of malignant breast cancer and has been involved in mammary cell 
proliferation and transformation (Lu, Shen et al. 2005; Motrich, Castro et al. 2013). The HSPB2 
gene encodes for a protein which belongs to the superfamily of small heat-shock proteins, 
which are normally induced under environmental stress (Georgopoulos and Welch 1993). Up 
to date, there are numerous studies linking this protein to breast cancer, for example HSPB is 
known to serve as a risk factor of malignant progression in benign proliferating breast lesions 
and is associated with resistance to Herceptin and other agents (O'Neill, Shaaban et al. 2004; 
Kang, Kang et al. 2008). Lastly, the AGR3 gene, also called breast cancer membrane protein 11 
(BCMP11), was initially identified in membranes of breast cancer cell lines (Adam, Boyd et al. 
2003). AGR3 is implicated in the growth and metastasis of hormone-responsive breast tumors 
and has been associated with survival and differentiation in ovarian cancer (Fletcher, Patel et 
al. 2003; King, Tung et al. 2011). Clearly, more functional studies will be necessary in order to 
make a conclusion about the role of these genes in the response of patients to this treatment. 
Finally, the miRNA expression profiling and its integration with gene expression were 
performed to further complete our understanding of the response of cells to OLP. All three 
groups of LCLs showed significant OLP-induced changes of miRNome, among which most of 
the DEm (applying the stringent significance threshold of FDR < 0.05) were common for all 
LCLs. As the miRNAs are negative regulators of gene expression, we performed an integration 
study between DEm and DEg and selected those miRNAs and their target genes whose 
expression negatively correlated. As in the case of gene expression profile, we were initially 
interested in the common response of WT cells to OLP and then we checked the behaviour of 
selected targets in mutated cells. What caught our attention was that OLP increased the 
expression of miR-222-3p which has been previously validated to target FOS gene (Errico, 
Felicetti et al. 2013), and miR-548ap-5p which is silencing the ERBB2 gene (Chen, Sun et al. 
2009). Therefore it seems that, in WT cells, OLP stimulates expression of these two miRNAs 
which in turns leads to a downregulation of the expression of breast cancer-associated genes 
ERBB2 and FOS. Surprisingly, we found a completely opposite regulation of miR-222-3p and its 
target FOS by OLP treatment in cells carrying missense, but not truncating, mutation in BRCA1 
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gene. Taking these results into account, we speculate that OLP could induce a favorable effect 
by FOS downregulation in non-carriers or patients carrying truncating mutation, whereas this 
effect is not induced in patients with G1706E and A1708E missense mutations in BRCA1. 
Overall, our results suggest that carriers of different types of BRCA1 mutations could 
benefit from the treatment in a distinct way and could show different toxicity to PARP inhibitor 
OLP. It is also possible that BRCA1 mutation type could be at least partially responsible for the 
observed huge variability in response to this agent in patients. Our findings are also relevant 
for the potential use of PARP inhibitors as prophylactic agents in BRCA1 mutation carriers, 
because such treatment is likely to lead to variable responses, depending on the mutation type 
of the carrier. In addition, considering our results and that two of the three most recurrent 
mutations in Spain are missense mutation, further research on differences between BRCA1 
mutation types could be of a great importance, particularly in this population. 
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1. Carriers of BRCA1 truncating mutation express less BRCA1 mRNA and protein, most 
probably due to degradation of the non-stable truncated transcripts by the NMD 
pathway. On the contrary, cells harboring the missense mutations p.Ala1708Glu and 
p.Gly1706Glu show similar average mRNA and protein expression levels as controls, which 
opens up the possibility of a putative dominant-negative effect. 
 
2. At the basal conditions, LCLs established from carriers of heterozygous truncating 
mutations showed increased level of DNA damage. Both missense and truncating mutants 
showed impaired DNA repair, indicated by decreased ability to form RAD51 foci. These 
results suggest haploinsufficiency of the mutated cells in DNA repair and a possible 
mechanism of increased susceptibility of carriers to cancer  
 
3. Gene expression profiles vary depending on the BRCA1 mutation status. Cells carrying 
missense mutations tend to cluster away from the rest and have the most distinct gene 
expression profile, showing overrepresentation of downregulated immune response-
related genes. These results indicate that different mutations could have different 
phenotypic effects. 
 
4. Cells derived from carriers of truncating mutations showed similar sensitivity to the PARP 
inhibitor olaparib as non-mutated controls. However, carrying a missense mutation in the 
BRCA1 gene increased the sensitivity of the cells to this agent. Our results strongly 
indicate that carriers of different types of BRCA1 mutations could benefit from the 
treatment in a distinct way and that could show different toxicity to the PARP inhibitor 
olaparib 
 
5. Proteomic analysis of BRCA1 BRCT protein interactors revealed downregulation of BRCA1-
A complex binding upon treatment with olaparib. This PARP inhibitor also induced 
phosphorylation of a threonine residue at BRCA1 BRCT domain at position 1834 which has 
not been previously reported and could therefore be a new marker of response to 
olaparib. 
 
6. In normal cells, olaparib increased the expression of miR-548ap-5p and miR-222-3p which 
are targeting ERBB2 and FOS genes, respectively. These genes were significantly 
downregulated as a response to olaparib treatment. Interestingly, the opposite regulation 
of miR-222-3p and its target FOS by olaparib treatment in cells carrying missense 
mutation suggest a possible use of these molecules as markers of sensitivity to the 
treatment. 
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1. Las portadoras de mutaciones de proteína truncada en heterocigosis en el gen BRCA1 
expresan niveles más bajos de ARNm y proteína, probablemente debido a la degradación 
de los transcritos no estables a través del mecanismo NMD. Por el contrario, las células 
portadoras de mutaciones de tipo cambio de aminoácido (missense) p.Ala1708Glu and 
p.Gly1706Glu muestran niveles de ARNm y proteína similares a los controles, lo que abre 
la posibilidad de que ejerzan un posible efecto dominante-negativo. 
 
2. En condiciones basales, las LCLs establecidas a partir de portadoras de mutaciones de 
proteína truncada mostraron los mayores niveles  de daño en el ADN. Tanto las LCLs 
portadoras de mutaciones de proteína truncada, como las portadoras de mutaciones 
missense mostraron defectos en la reparación del ADN, indicada por una reducción en la 
formación de focos de la proteína RAD51. Estos resultados sugieren que las células 
portadoras de mutaciones en heterocigosis en BRCA1 son haploinsuficientes para la 
reparación del daño en el ADN. 
 
3. Los perfiles de expresión génica de las LCLs portadoras de mutaciones en heterocigosis en 
el gen BRCA1 varían dependiendo del tipo de mutación. Las portadoras de mutaciones 
missense mostraron el perfil de expresión más diferente, observándose una 
sobrerepresentación de genes implicados en la respuesta inmune con niveles de 
expresión reducidos. Estos resultados sugieren que las diferentes mutaciones pueden 
tener distintos efectos fenotípicos. 
 
4. Las células derivadas de portadoras de mutaciones de proteína truncada en heterocigosis 
mostraron la misma sensibilidad que los controles al inhibidor de PARP olaparib. Sin 
embargo las células portadoras de mutaciones missense mostraron una sensibilidad 
incrementada al fármaco. Nuestros resultados sugieren que portadores de diferentes 
tipos de mutaciones en BRCA1 podrían beneficiarse de forma distinta del tratamiento con 
olaparib y presentar distinta toxicidad al mismo.  
 
5. El análisis de las proteínas que interaccionan con el dominio BRCT de BRCA1 reveló una 
regulación negativa del complejo BRCA1-A tras el tratamiento con olaparib. El tratamiento 
también indujo la fosforilación de un residuo treonina en la posición 1834 de BRCA1 que 
no ha sido previamente descrito. Estas modificaciones podrían ser importantes de cara a 
entender el mecanismo de sensibilidad de las células a olaparib. 
 
6. En las células normales, el tratamiento con olaparib aumenta la expresión de miR-548ap-
5p y miR-222-3p que actúan sobre los genes ERBB2 y FOS respectivamente. La expresión 
de estos genes disminuyó de una forma estadísticamente significativa tras el tratamiento 
con olaparib. Encontramos un efecto contrario en la regulación de estos genes en las 
células con mutaciones missense, las más sensibles al tratamiento, sugiriendo que estos 
miRNAs y genes podrían ser marcadores de sensibilidad al mismo. 
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Supplementary Figure S1. Effect of the BRCA1 germline mutation on the level of DNA damage and 
repair. (A) High-throughput microscopy quantification of gamma-H2AX signal intensity in nuclei of WT 
LCLs or cells harboring monoallelic missense or truncating mutation in BRCA1. The data represent a 
signal intensity detected in 240 individual nuclei of each LCL in the group and the grey line indicates 
mean intensity of the gamma-H2AX signal. The differences between groups were evaluated using Mann-
Whitney U test (*** represents P<0.001) (B) Average number of RAD51 foci per nucleus in control cells 
or cells with heterozygous missense or truncating mutation in BRCA1. The data represent a mean from 
240 analyzed nuclei of each LCL in the particular group +/- SEM.  The P-value was calculated using Mann-
Whitney U test (** represents P<0.01). 
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Supplementary Figure S2. Involvement of the differentially expressed genes in cells with missense 
mutation in cell death and inflammatory response pathways. The network shows interaction of 27 (cell 
death pathway) and 16 (inflammatory response pathway) genes. Underlined genes belong to our set of 
differentially expressed genes between WTs and cells with missense mutation in BRCA1. The legend 
specifies the molecule type and type of interaction between molecules. 
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Supplementary Figure S3. Differentially expressed miRNAs in groups of LCLs carrying WT or mutated 
BRCA1. Venn diagram and a table illustrating the number and names of miRNAs being differentially 
expressed (unadjusted P-value ≤ 0.05) between LCLs harboring WT, missense (MIS) or truncated (TRUN) 
BRCA1. 
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Supplementary Table S1. List of human GIPZ lentiviral shRNAmir set against BRCA1 
Gene 
target 
shRNA 
name 
Catalog 
number 
Clone ID Location Host 
Vector 
name 
Vector 
type 
Resistance 
BRCA1 sh1 
RHS4430-
98708636 
V2LHS_238842 172_0156-G -6 human pGIPZ lentiviral 
Zeocin, 
Ampicillin 
BRCA1 sh2 
RHS4430-
98820503 
V2LHS_254609 172_0156-G -6 human pGIPZ lentiviral 
Zeocin, 
Ampicillin 
BRCA1 sh3 
RHS4430-
98914030 
V2LHS_198913 172_0156-G -6 human pGIPZ lentiviral 
Zeocin, 
Ampicillin 
BRCA1 sh4 
RHS4430-
99139237 
V2LHS_280394 172_0156-G -6 human pGIPZ lentiviral 
Zeocin, 
Ampicillin 
BRCA1 sh5 
RHS4430-
99148123 
V2LHS_90880 172_0156-G -6 human pGIPZ lentiviral 
Zeocin, 
Ampicillin 
BRCA1 sh6 
RHS4430-
99157192 
V2LHS_254648 172_0156-G -6 human pGIPZ lentiviral 
Zeocin, 
Ampicillin 
 
Supplementary Table S2. Molecular and cellular functions related to genes differentially expressed in 
WTs and cells with missense mutation in BRCA1. 
Molecular and cell functions  p-value Molecules involved (from our dataset) 
Cell Death and Survival 1,58E-05-4,48E-02 WNT11,IFNG,ICOS,PPARG,IRF5 
Cellular Development 1,95E-05-4,48E-02 ITGB5,IFNG,ICOS,PPARG 
Cell-To-Cell Signaling and Interaction 1,97E-05-3,61E-02 ITGB5,IFNG,ICOS,PPARG 
Cellular Movement 5,12E-05-4,94E-02 WNT11,ITGB5,ICOS,IFNG,PPARG 
Cellular Growth and Proliferation 2,3E-04-4,48E-02 ADCY1,PLS3,ITGB5,IFNG,ICOS,PPARG 
Amino Acid Metabolism 6,93E-04-6,93E-04 IFNG 
Cell Cycle 6,93E-04-1,99E-02 IFNG,PPARG 
Cell Morphology 6,93E-04-4,41E-02 PLS3,ICOS,IFNG,PPARG 
Cell Signaling 6,93E-04-3,07E-02 ADCY1,IFNG,PPARG 
Cellular Compromise 6,93E-04-1,17E-02 IFNG,ICOS 
Cellular Function and Maintenance 6,93E-04-4,35E-02 PLS3,IFNG,ICOS,PPARG 
DNA Replication, Recombination, and 
Repair 
6,93E-04-2,13E-02 IFNG 
Gene Expression 6,93E-04-3,85E-02 IFNG,PPARG 
Lipid Metabolism 6,93E-04-4,74E-02 IFNG,PPARG 
Molecular Transport 6,93E-04-4,74E-02 IFNG,ICOS,PPARG 
Nucleic Acid Metabolism 6,93E-04-2,15E-02 DDX43,ADCY1,IFNG 
Protein Trafficking 6,93E-04-6,93E-04 ICOS 
Small Molecule Biochemistry 6,93E-04-4,74E-02 DDX43,ADCY1,IFNG,PPARG 
Drug Metabolism 1,38E-03-1,1E-02 IFNG,PPARG 
RNA Post-Transcriptional Modification 1,39E-03-3,46E-03 IFNG 
Cellular Assembly and Organization 2,77E-03-4,41E-02 PLS3,IFNG,ICOS 
Cellular Response to Therapeutics 2,77E-03-2,77E-03 IFNG 
Vitamin and Mineral Metabolism 2,77E-03-2,77E-03 IFNG 
Carbohydrate Metabolism 3,46E-03-2,33E-02 IFNG,PPARG 
Free Radical Scavenging 1,1E-02-4,08E-02 IFNG 
Energy Production 3,48E-02-3,48E-02 PPARG 
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Supplementary Table S3. Molecular and cellular functions related to genes differentially expressed in 
WTs and cells with truncating mutation in BRCA1. 
Molecular and cell functions  p-value Molecules involved (from our dataset) 
Cellular Movement 2.31E-04-1.11E-02 LY6D,MMP7 
Cellular Development 3.46E-04-1.2E-02 MMP7 
Cellular Growth and Proliferation 3.46E-04-1.2E-02 MMP7 
Cell-To-Cell Signaling and Interaction 4.62E-04-4.62E-04 MMP7 
Cell Death and Survival 1.31E-02-2.84E-02 MMP7 
Post-Translational Modification 1.56E-02-1.56E-02 MMP7 
Protein Degradation 1.56E-02-1.56E-02 MMP7 
Protein Synthesis 1.56E-02-1.56E-02 MMP7 
 
Supplementary Table S4. BRCA1 BRCT protein interactors identified by mass spectrometry in DMSO- 
or OLP-treated HEK293FT cells. 
Gene Gene name 
Protein 
(UniProtKB / 
Swiss-Prot) 
Mr 
(kDa) 
DMSO OLP 
Fold change 
(OLP/DMSO) 
BRCA1 Breast cancer type 1 susceptibility protein  BRCA1 208 163 150 0.9 
BRIP1 Fanconi anemia group J protein  FANCJ 141 81 80 1.0 
ANKRD26 Ankyrin repeat domain-containing protein 26  ANR26 196 72 81 1.1 
POLR2A DNA-directed RNA polymerase II subunit RPB1  RPB1 217 64 64 1.0 
UIMC1 BRCA1-A complex subunit RAP80  UIMC1 80 55 50 0.9 
POLR2B DNA-directed RNA polymerase II subunit RPB2  RPB2 134 53 59 1.1 
RBBP8 DNA endonuclease RBBP8  COM1 102 52 54 1.0 
NUMB Protein numb homolog  NUMB 71 37 39 1.1 
PRKDC 
DNA-dependent protein kinase catalytic 
subunit  
PRKDC 469 29 33 1.1 
DOCK7 Dedicator of cytokinesis protein 7  DOCK7 243 27 47 1.7 
BRCC3 Lys-63-specific deubiquitinase BRCC36  BRCC3 36 27 21 0.8 
RPAP2 
Putative RNA polymerase II subunit B1 CTD 
phosphatase RPAP2  
RPAP2 70 23 26 1.1 
BABAM1 BRISC and BRCA1-A complex member 1  BABA1 37 21 25 1.2 
SUPT6H Transcription elongation factor SPT6  SPT6H 199 20 14 0.7 
MYO6 Unconventional myosin-VI  MYO6 150 19 29 1.5 
RECQL5 ATP-dependent DNA helicase Q5  RECQ5 109 19 17 0.9 
CEP350 Centrosome-associated protein 350  CE350 351 18 27 1.5 
FAM175A BRCA1-A complex subunit Abraxas  F175A 47 18 14 0.8 
AMOT Angiomotin  AMOT 118 17 50 2.9 
POLR2C DNA-directed RNA polymerase II subunit RPB3  RPB3 31 16 11 0.7 
POLR2E 
DNA-directed RNA polymerases I, II, and III 
subunit RPABC1  
RPAB1 25 15 12 0.8 
GRL1A 
DNA-directed RNA polymerase II subunit 
GRINL1A  
GRL1A 42 14 12 0.9 
POLR2H 
DNA-directed RNA polymerases I, II, and III 
subunit RPABC3  
RPAB3 17 14 10 0.7 
ANKRD28 
Serine/threonine-protein phosphatase 6 
regulatory ankyrin repeat subunit A  
ANR28 113 14 6 0.4 
MRPS22 28S ribosomal protein S22, mitochondrial  RT22 41 13 10 0.8 
MRPS27 28S ribosomal protein S27, mitochondrial  RT27 48 13 9 0.7 
ZDHHC5 Palmitoyltransferase ZDHHC5  ZDHC5 78 12 15 1.3 
WBP11 WW domain-binding protein 11  WBP11 70 12 15 1.3 
KIAA1671 Uncharacterized protein KIAA1671  K1671 197 10 29 2.9 
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DOCK6 Dedicator of cytokinesis protein 6  DOCK6 230 10 19 1.9 
RFC4 Replication factor C subunit 4  RFC4 40 10 7 0.7 
RICTOR Rapamycin-insensitive companion of mTOR RICTR 192 9 17 1.9 
BRE BRCA1-A complex subunit BRE  BRE 44 9 10 1.1 
RFC2 Replication factor C subunit 2  RFC2 39 9 7 0.8 
KIAA1211 Uncharacterized protein KIAA1211  K1211 137 8 16 2.0 
NUMBL Numb-like protein  NUMBL 65 8 11 1.4 
POLR2G DNA-directed RNA polymerase II subunit RPB7  RPB7 19 8 7 0.9 
MRPS18B 28S ribosomal protein S18b, mitochondrial  RT18B 29 8 5 0.6 
GTF2F1 General transcription factor IIF subunit 1  T2FA 58 7 10 1.4 
TRRAP 
Transformation/transcription domain-
associated protein  
TRRAP 438 7 9 1.3 
COBL Protein cordon-bleu  COBL 136 7 8 1.1 
HNRNPA0 Heterogeneous nuclear ribonucleoprotein A0  ROA0 31 7 8 1.1 
RFC5 Replication factor C subunit 5  RFC5 38 7 6 0.9 
RBM19 Probable RNA-binding protein 19  RBM19 107 7 4 0.6 
CTTNBP2NL CTTNBP2 N-terminal-like protein  CT2NL 70 6 16 2.7 
CDK16 Cyclin-dependent kinase 16  CDK16 56 6 12 2.0 
DAP3 28S ribosomal protein S29, mitochondrial  RT29 46 6 8 1.3 
ZFC3H1 Zinc finger C3H1 domain-containing protein  ZC3H1 226 6 7 1.2 
MAST2 
Microtubule-associated serine/threonine-
protein kinase 2  
MAST2 196 6 7 1.2 
PIP5K1A 
Phosphatidylinositol 4-phosphate 5-kinase 
type-1 alpha  
PI51A 63 6 5 0.8 
RFC3 Replication factor C subunit 3  RFC3 41 6 5 0.8 
AKAP12 A-kinase anchor protein 12  AKA12 191 6 4 0.7 
RRP7A 
Ribosomal RNA-processing protein 7 homolog 
A  
RRP7A 32 6 4 0.7 
ANKRD44 
Serine/threonine-protein phosphatase 6 
regulatory ankyrin repeat subunit B  
ANR44 108 6 2 0.3 
PDCD6 Programmed cell death protein 6  PDCD6 22 6 0 0.0 
LRCH2 
Leucine-rich repeat and calponin homology 
domain-containing protein 2  
LRCH2 85 5 13 2.6 
RNGTT mRNA-capping enzyme  MCE1 69 5 13 2.6 
PPP1R18 Phostensin  PPR18 68 5 11 2.2 
MRPS5 28S ribosomal protein S5, mitochondrial  RT05 48 5 8 1.6 
LUZP1 Leucine zipper protein 1  LUZP1 120 5 7 1.4 
POLR2D DNA-directed RNA polymerase II subunit RPB4  RPB4 16 5 7 1.4 
COPE Coatomer subunit epsilon  COPE 34 5 6 1.2 
PPP6R1 
Serine/threonine-protein phosphatase 6 
regulatory subunit 1  
PP6R1 97 5 3 0.6 
TIMM50 
Mitochondrial import inner membrane 
translocase subunit TIM50  
TIM50 40 5 3 0.6 
PPP6C 
Serine/threonine-protein phosphatase 6 
catalytic subunit  
PPP6 35 5 2 0.4 
CDKN2AIP CDKN2A-interacting protein  CARF 61 4 10 2.5 
ARHGAP21 Rho GTPase-activating protein 21  RHG21 217 4 8 2.0 
PIK3C2A 
Phosphatidylinositol 4-phosphate 3-kinase C2 
domain-containing subunit alpha  
P3C2A 191 4 6 1.5 
ZFP36L2 Zinc finger protein 36, C3H1 type-like 2  TISD 51 4 6 1.5 
MRPS35 28S ribosomal protein S35, mitochondrial  RT35 37 4 5 1.3 
HELZ Probable helicase with zinc finger domain  HELZ 219 4 3 0.8 
PPP6R2 
Serine/threonine-protein phosphatase 6 
regulatory subunit 2  
PP6R2 105 4 3 0.8 
SSBP4 Single-stranded DNA-binding protein 4  SSBP4 39 4 3 0.8 
L3MBTL3 Lethal(3)malignant brain tumor-like protein 3  LMBL3 88 4 2 0.5 
GPN3 GPN-loop GTPase 3  GPN3 33 4 2 0.5 
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POLR2I DNA-directed RNA polymerase II subunit RPB9  RPB9 15 4 2 0.5 
MRPS16 28S ribosomal protein S16, mitochondrial  RT16 15 4 2 0.5 
SRPRB 
Signal recognition particle receptor subunit 
beta  
SRPRB 30 4 1 0.3 
ANKRD17 Ankyrin repeat domain-containing protein 17  ANR17 274 3 8 2.7 
RANBP2 E3 SUMO-protein ligase RanBP2 RBP2 358 3 7 2.3 
SAMD1 Atherin  SAMD1 56 3 6 2.0 
ZNF318 Zinc finger protein 318  ZN318 251 3 5 1.7 
LRCH3 
Leucine-rich repeat and calponin homology 
domain-containing protein 3  
LRCH3 86 3 5 1.7 
MEX3C 
RNA-binding E3 ubiquitin-protein ligase 
MEX3C  
MEX3C 69 3 5 1.7 
ATXN2 Ataxin-2  ATX2 140 3 4 1.3 
MAPKAP1 
Target of rapamycin complex 2 subunit 
MAPKAP1  
SIN1 59 3 3 1.0 
EXOSC2 Exosome complex component RRP4  EXOS2 33 3 3 1.0 
GPATCH4 G patch domain-containing protein 4  GPTC4 50 3 2 0.7 
IMP4 
U3 small nucleolar ribonucleoprotein protein 
IMP4  
IMP4 34 3 2 0.7 
MPHOSPH10 
U3 small nucleolar ribonucleoprotein protein 
MPP10  
MPP10 79 3 1 0.3 
PRR5 Proline-rich protein 5  PRR5 43 3 1 0.3 
DRG1 
Developmentally-regulated GTP-binding 
protein 1  
DRG1 41 3 1 0.3 
ZNF346 Zinc finger protein 346  ZN346 33 3 1 0.3 
EXOSC4 Exosome complex component RRP41  EXOS4 26 3 1 0.3 
PRDX5 Peroxiredoxin-5, mitochondrial  PRDX5 22 3 0 0.0 
MICAL3 Protein-methionine sulfoxide oxidase MICAL3  MICA3 224 2 8 4.0 
MYLK Myosin light chain kinase, smooth muscle  MYLK 211 2 7 3.5 
PPP6R3 
Serine/threonine-protein phosphatase 6 
regulatory subunit 3  
PP6R3 98 2 7 3.5 
ITPKA Inositol-trisphosphate 3-kinase A  IP3KA 51 2 6 3.0 
FGFR1OP FGFR1 oncogene partner  FR1OP 43 2 6 3.0 
ZNF638 Zinc finger protein 638  ZN638 221 2 5 2.5 
SHROOM2 Protein Shroom2  SHRM2 176 2 5 2.5 
AFAP1 Actin filament-associated protein 1  AFAP1 81 2 3 1.5 
CCDC59 
Thyroid transcription factor 1-associated 
protein 26  
TAP26 29 2 3 1.5 
TPRN Taperin  TPRN 76 2 2 1.0 
GALK1 Galactokinase  GALK1 42 2 2 1.0 
DNAJC9 DnaJ homolog subfamily C member 9  DNJC9 30 2 2 1.0 
AMOTL1 Angiomotin-like protein 1  AMOL1 107 1 14 14.0 
AMBP Protein AMBP  AMBP 39 1 4 4.0 
DHRS7B 
Dehydrogenase/reductase SDR family 
member 7B  
DRS7B 35 1 2 2.0 
INF2 Inverted formin-2  INF2 136 0 7 7.0 
ARID3B 
AT-rich interactive domain-containing protein 
3B  
ARI3B 61 0 7 7.0 
ITPKB Inositol-trisphosphate 3-kinase B  IP3KB 102 0 5 5.0 
STRN Striatin  STRN 86 0 5 5.0 
ANKHD1 
Ankyrin repeat and KH domain-containing 
protein 1  
ANKH1 269 0 4 4.0 
AP2A1 AP-2 complex subunit alpha-1  AP2A1 108 0 4 4.0 
STRN3 Striatin-3  STRN3 87 0 4 4.0 
CCDC102A Coiled-coil domain-containing protein 102A  C102A 63 0 4 4.0 
NUMA1 Nuclear mitotic apparatus protein 1  NUMA1 238 0 3 3.0 
MYO18A Unconventional myosin-XVIIIa  MY18A 233 0 3 3.0 
BORA Protein aurora borealis  BORA 61 0 3 3.0 
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